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ABSTRACT 
 
Combined deficiency of coagulation factors V and VIII (F5F8D) is a human 
autosomal recessive bleeding disorder caused by defects in LMAN1 or MCFD2.  These 
proteins form a complex, which facilitates secretion of coagulation factors V (FV) and 
VIII (FVIII), serving as the only known cargo-receptor in the mammalian secretory 
pathway.  F5F8D patients exhibit FV and FVIII levels that are ~10-15% of normal.  This 
dissertation focuses on three major questions regarding F5F8D pathophysiology.  First, to 
answer a long-standing question in the hemostasis field, what is the cellular source of 
FVIII biosynthesis?  Second, what is the relationship between Lman1 expression level 
and the corresponding secretion of FV and FVIII?  Third, can additional LMAN1-
dependent cargos be identified?  
          Although hepatocytes and megakaryocytes are the known biosynthetic sources of 
murine FV, the primary cellular source of FVIII biosynthesis is controversial, with 
contradictory evidence supporting an endothelial or hepatocyte origin.  Conditional 
knockout mice with Lman1 deleted in the endothelium or the hepatocytes were generated 
in order to determine the relative contribution of these two tissues to the plasma FVIII 
pool.  The endothelium-knockout mice exhibit normal FV levels, but significantly 
reduced FVIII levels.  Conversely, hepatocyte-specific knockout mice exhibit normal 
FVIII levels, but low FV levels.  These results indicate that endothelial cells are the 
primary site of FVIII biosynthesis, and that hepatocytes do not significantly contribute to 
the plasma FVIII pool.  qRT-PCR analysis of endothelial cell-specific mRNA confirmed 
the endothelial-specific expression of F8, and demonstrated extensive heterogeneity of 
F8 expression in different vascular beds, with the highest expression in the endothelial 
cells of liver and kidney. 
          A series of LMAN1-deficient mice with variable Lman1 expression levels (0% to 
~7% of normal) was generated.  LMAN1-null mice exhibit FV and FVIII levels that are 
~50% of normal (versus ~10-15% in human patients), while mice expressing ~7% of 
 xiii 
wild-type Lman1 levels show an intermediate reduction in FV and FVIII (~70% of wild-
type levels).  A similar result was demonstrated for alpha-1 antitrypsin secretion, another 
LMAN1-dependent cargo.  Given that nearly all reported LMAN1 F5F8D patients carry 
two null LMAN1 alleles, our results suggest that hypomorphic LMAN1 mutations in 
humans may result in milder phenotypes that are missed clinically.  LMAN1-null mice 
also demonstrate a partially penetrant, strain-specific, perinatal lethality.  This result 
suggests a broader role for murine LMAN1 in protein secretion in addition to FV and 
FVIII.  LMAN1-deficient mice also exhibit a mild thrombocytopenia that has not been 
observed in humans, suggesting a potential role for LMAN1 in platelet development.   
In preliminary studies, proteomic profiling of mouse tissues by mass-spectrometry 
and yeast-two-hybrid assays were applied in an effort to identify novel LMAN1/MCFD2 
cargos and interacting proteins.  Comparison of plasma samples from Lman1+/+ and 
Lman1-/- mice by mass-spectrometry revealed SERPINA3K, a serine protease inhibitor, 
as a potential novel LMAN1 cargo that was in lower abundance in the plasma of 
LMAN1-deficient mice than wild-type mice.  Complement component C3, a serine 
protease, was also under-represented in the plasma of Lman1-/- mice.  It is possible that 
SERPINA3K and complement component C3 cleavage fragments represent newly 
identified protease/protease inhibitor complexes, and that the efficient secretion of one of 
these components to the plasma is LMAN1-dependent.   
Taken together, the work outlined here provides new insight into the function of 
LMAN1/MCFD2 in the mammalian secretory pathway and the phenotype of LMAN1-
deficiency in vivo.   
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CHAPTER 1 : 
INTRODUCTION  
 
COMBINED DEFICIENCY OF COAGULATION FACTORS V AND VIII 
 
Defects in the synthesis, secretion, and function of coagulation factors V (FV) and VIII 
(FVIII) are important causes of inherited bleeding disorders.  FV and FVIII are large, 
secreted glycoproteins (280-330 kDa) with critical roles in hemostasis and thrombosis.  
FV and FVIII function as essential cofactors for the proteolytic activation of prothrombin 
and factor X in the coagulation cascade, respectively.  Genetic deficiency of FVIII results 
in hemophilia A, whereas inherited FV deficiency results in parahemophilia.  A gain-of-
function mutation (FV Leiden) or increased FVIII activity are both major risk factors for 
venous thrombosis.1,2  Finally, combined deficiency of factors V and VIII (F5F8D, 
OMIM 227300) is an autosomal recessive bleeding disorder characterized by reduction of 
both FV and FVIII to ~10-15% of normal levels.3,4  F5F8D was first identified and 
described in two brothers by Oeri et al. in 1954.5  The molecular etiology of F5F8D is 
distinct from that of parahemophilia or hemophilia A, resulting from impaired post-
translational secretion of FV and FVIII, rather than from a defect within the F5 or F8 
genes.   
 
Epidemiology 
Data on the epidemiology of F5F8D and the distribution of this disease around the world 
are available in the Rare Bleeding Disorders Database (http://www.rbdd.org) and from 
the World Federation of Hemophilia (WFH) global survey 
(http://www1.wfh.org/publications/files/pdf-1488.pdf). 
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F5F8D is an autosomal recessive disorder; males and females are affected equally.  
F5F8D is extremely rare in the general population (1:1,000,000), although it is observed 
with a higher frequency in populations with consanguineous marriages.6-8  As compared 
to the general population, the prevalence of F5F8D is much higher among Middle Eastern 
Jewish individuals and non-Jewish Iranians (~1:100,000).9  Most reported cases of 
F5F8D are from Iran and Italy, with smaller numbers of case reports originating in 
Pakistan, Iraq, Lebanon, and Algeria.6  Additional cases have been reported from 
European countries, India, Asian countries such as Japan, China, and Thailand, and also 
from South Africa, the United States, and South America.6  Overall, the global 
distribution of F5F8D patients is broad with variable frequencies, with the majority of 
new F5F8D cases in Middle-Eastern countries and India, an intermediate frequency in 
South America and Asia, and a small proportion of cases in North America, Europe, and 
Africa.6  As of 2004, at least 140 patients in 81 families had been diagnosed with 
F5F8D.10  According to the 2011 World Federation of Hemophilia Global Survey, 62 
countries reported a current total of 352 F5F8D patients.11  However, given the mild 
bleeding manifestations in most F5F8D patients, it is likely that F5F8D is under-
diagnosed, or that patients with F5F8D may be misdiagnosed with mild hemophilia A or 
parahemophilia.  Accurate data about the global distribution of F5F8D is also lacking 
because many countries do not maintain reliable national registries, and there are 
probably higher rates of detection and accurate F5F8D diagnosis in countries with higher 
F5F8D prevalence.  There are 117 LMAN1 variants reported in the University of 
Washington Exome Variant Server database.12  Among European Americans represented 
in the database, the frequency of these variants is ~1/8,500, while the frequency is 
~1/4,400 among African Americans.  Of the 117 LMAN1 variants in the database, 24 are 
synonymous coding variants, 31 are missense variants, 1 is a 3’ UTR variant, and 1 is a 
frameshift mutation.  
 
Clinical Presentation 
F5F8D results in mild-to-moderate bleeding symptoms associated with prolonged 
prothrombin time (PT) and partial thromboplastin time (PTT) due to deficiency of FV 
and FVIII, respectively.7-9,13  The FV and FVIII levels (both activity and antigen) in most 
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F5F8D patients are ~10-15% of normal.3,4  Easy bruising, epistaxis, and excessive 
bleeding during or after trauma are some of the most common symptoms, as well as 
menorrhagia and postpartum hemorrhage in affected women.9,14  However, more severe 
bleeding symptoms may include hemarrthroses, muscular hematomas, umbilical cord 
bleeding, and rarely gastrointestinal and central nervous system bleeding.6  F5F8D 
patients have normal VWF levels, as is the case for hemophilia A patients.9  Except for 
the isolated combined deficiency of FV and FVIII, there are currently no other known 
clinical phenotypes associated with F5F8D.  The primary goal of treatment for bleeding 
episodes in F5F8D patients is replacement of FV and FVIII, but specific management is 
determined on a case-by-case basis by the nature of the bleeding and the FV and FVIII 
levels of the patient.6  Prophylactic treatment is not usually necessary, but may be used in 
cases of severe recurrent bleeding.  
 
 
PATHOPHYSIOLOGY OF F5F8D 
 
LMAN1/MCFD2 cargo receptor 
F5F8D is caused by mutations in LMAN1 (also known as ERGIC-53) or MCFD2, which 
result in a defect in the early secretory pathway and the impaired secretion of FV and 
FVIII to the plasma.3,4  LMAN1 is encoded by a ~29 kb gene (13 exons) located on 
chromosome 18q21, and MCFD2 is encoded by a ~19 kb gene (4 exons) located on 
chromosome 2p21.  LMAN1 and MCFD2 bind together in a 1:1 ratio to form the only 
known mammalian secretory cargo adaptor/receptor complex.  The LMAN1/MCFD2 
complex is responsible for efficient secretion of FV and FVIII to the plasma.  F5F8D is 
therefore an example of locus heterogeneity, in which identical phenotypes result from 
mutations at two or more distinct genetic loci.  Although the clinical features of F5F8D 
are similar to that of FV deficiency (parahemophilia, chromosome 1) and FVIII 
deficiency (hemophilia A, chromosome X), the inheritance of F5F8D is distinct from the 
coinheritance of both of these disorders.  Whereas parahemophilia and hemophilia A 
result from defects in the F5 and F8 genes, F5F8D results from the impaired post-
 4 
translational secretion of FV and FVIII to the plasma mediated by the shared 
LMAN1/MCFD2 secretory cargo receptor.  
 
LMAN1 is a homo-hexameric, 53-kDa type I transmembrane receptor protein (510 amino 
acids) that spans the ER membrane.  The protein structure consists of a 480 amino acid 
ER luminal domain, a transmembrane domain, and a short 12 amino acid cytoplasmic tail 
domain (Figure 1-1A).  The luminal domain includes an N-terminal carbohydrate 
recognition domain (CRD, ~200 amino acids) and a membrane-proximal α-helical coiled 
domain (the stalk domain).  The CRD is homologous to other lectin domains known to 
bind mannose-rich glycoproteins.  The LMAN1 C-terminal cytosolic tail domain contains 
both a di-phenylalanine ER-exit motif (FF) and a di-lysine ER-retrieval signal (KK).  The 
di-phenylalanine motif allows for interactions with components of COPII vesicle coats, 
promoting efficient ER export of LMAN1 and its bound cargos.15  The di-lysine motif 
serves as an ER retrieval signal for LMAN1,16 facilitating the constitutive recycling of 
LMAN1 between the endoplasmic reticulum (ER) and the Endoplasmic Reticulum Golgi 
Intermediate Compartment (ERGIC) in the early secretory pathway (Figure 1-2).17   
 
LMAN1 was discovered in 1988,18 and has been used extensively as a molecular marker 
for the ERGIC since that time.  However, its function as a secretory cargo receptor 
remained unknown for many years.  LMAN1 is a member of a family of homologous 
leguminous type (L-type) mannose-binding lectins,19-21 along with VIP36,22 VIPL,23,24 
and ERGL.25  The L-type lectins share similar carbohydrate recognition domains, but 
they have different subcellular localization patterns, distinct glycoprotein-binding 
specificities, and different pH optima for glycoprotein binding.26,27  The intracellular 
localization pattern of LMAN1 (cycling between the ER and the ERGIC) and the 
homology of LMAN1 to the family of mannose-binding lectins were two of the first 
indications that LMAN1 may function as a secretory cargo receptor in mammalian cells.  
The surprising identification of LMAN1 as the disease-causing gene in F5F8D provided 
the first direct evidence for LMAN1 as a mammalian ER-to-Golgi cargo receptor for FV 
and FVIII.4  In contrast, evidence suggests that the VIP36 homolog does not play a role in 
anterograde transport of secretory cargos (i.e. not an ER cargo receptor), but rather that it 
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binds glycoproteins in the Golgi19,28 (including A1AT) and recycles them back to the ER 
as part of a post-ER quality control mechanism.27,29,30  The lectin family member VIPL 
(VIP36-like) is more similar in sequence to VIP36 than to LMAN1, and is a non-cycling 
resident protein of the ER.24 
 
MCFD2 is a 16-kDa soluble luminal protein that contains two calmodulin-like EF-hand 
motifs (Figure 1-1B).  MCFD2 contains a signal sequence mediating translocation into 
the ER, but does not contain a C-terminal KDEL retrieval signal or any other identifiable 
sorting signal to direct its intracellular localization or recycling to the ER.  Rather, 
calcium-dependent interactions of the MCFD2 EF-hand domains with LMAN1 in the ER 
lumen cause MCFD2 to be retained in the early secretory pathway, co-localizing with 
LMAN1 to the ERGIC.3  
 
LMAN1 and MCFD2 bind via calcium-dependent interactions in a 1:1 stoichiometric 
ratio to form a hexameric complex at the ER membrane (Figure 1-1C).  This complex 
serves as a specific cargo receptor for the selective packaging of FV and FVIII into 
COPII-coated vesicles for subsequent ER-to-Golgi transport.3  LMAN1/MCFD2 then 
recycles from the ERGIC back to the ER to facilitate another round of secretory cargo 
transport.  LMAN1/MCFD2 complex formation is essential for cargo receptor function.  
MCFD2 missense mutations, particularly within the EF-hand domains, disrupt this 
interaction and cause F5F8D by abolishing the complex formation.31-33  Although both 
LMAN1 and MCFD2 are required for efficient secretion of FV and FVIII, LMAN1 binds 
some cargo glycoproteins in an MCFD2-independent manner.34,35  In the absence of 
MCFD2, LMAN1 is still localized properly to the ER and ERGIC.35  In contrast, in the 
absence of LMAN1, MCFD2 is secreted (MCFD2 is normally retained within the ER and 
the ERGIC due to its physical interactions with LMAN1).35 
 
Genetic analysis of F5F8D patients 
The underlying molecular pathophysiology of F5F8D was not understood until 1998, 
when Nichols et al. used homozygosity mapping and positional cloning to discover that 
homozygous or compound heterozygous mutations in LMAN1 account for ~70% of 
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F5F8D cases.4  In 2003, Zhang et al. identified MCFD2 as a second locus associated with 
F5F8D (~30% of cases),3 and it is now clear that homozygous or compound heterozygous 
mutations in either LMAN1 or MCFD2 are responsible for every reported case of 
F5F8D.36  No F5F8D patients have been reported with mutations in both LMAN1 and 
MCFD2.  As of 2013, the International Society on Thrombosis and Haemostasis and the 
Rare Bleeding Disorders Database (RBDD) of known mutations causing rare bleeding 
disorders documents 34 distinct LMAN1 mutations and 22 distinct MCFD2 mutations in 
F5F8D patients.  Three LMAN1 mutations are missense mutations, while the majority of 
mutations are predicted to be null (7 nonsense mutations, 7 splicing defect mutations, and 
17 deletion/insertions).  Two of the missense mutations are also likely to be functionally 
null alleles.  The first is a substitution of a threonine for the initiator methionine (codon 
1), which would interfere with normal translation initiation of LMAN1 and would be 
predicted to result in no functional protein product.  The second missense mutation is an 
arginine to cysteine substitution near the transmembrane domain.  This arginine residue is 
known to play an important role in the formation of inter-molecular disulfide bonds, 
which are important for LMAN1 oligomerization and function.37  The functional 
significance of this arginine to cysteine substitution was demonstrated in vitro and 
resulted in failed accumulation of the mutant LMAN1 in the cell, indicating that this 
mutant LMAN1 protein is likely unstable and nonfunctional.31  The abundance of null 
LMAN1 mutations in F5F8D patients is suggestive of a threshold effect of LMAN1 
function, but this has never been confirmed experimentally and no data exists about the 
relationship between LMAN1 expression levels and the level of LMAN1-dependent cargo 
secretion.   
 
Among the reported MCFD2 mutations, there are 11 missense mutations, one nonsense 
mutation, four splicing defect mutations, and six deletion/insertions.38  All missense 
mutations are localized to the EF-hand domains, which mediate interactions with 
LMAN1 as well as FV and FVIII.32  Missense mutations are sufficient to impair the 
interaction of MCFD2 with LMAN1, which results in F5F8D.31,32   
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Genotype-phenotype correlations 
Establishing genotype-phenotype correlations in rare bleeding disorders such as F5F8D is 
often difficult, primarily because the bleeding phenotypes are highly variable, even 
among patients with the same genotype.38  Modifier genes and environmental factors 
likely contribute to the variable severity of bleeding phenotypes among F5F8D patients, 
although no specific modifier genes for F5F8D clinical variability are currently known. 
 
F5F8D patients with MCFD2 mutations are reported to have slightly lower levels of FV 
and FVIII than patients with LMAN1 mutations,39 based on a review of available 
published data for 46 patients with MCFD2 mutations and 96 patients with LMAN1 
mutations.  This suggests that MCFD2 may play a more direct role in transporting FV 
and FVIII than does LMAN1, consistent with the finding that MCFD2 can bind to FVIII 
independent of LMAN1.40  Decreases in plasma FV and FVIII levels are correlated in 
F5F8D patients, and platelet FV levels are reduced to the same extent as plasma FV.36  
These data are consistent with the loss of function of the common ER-to-Golgi receptor 
complex for FV and FVIII.41   
 
 
THE CELLULAR SOURCE OF FVIII BIOSYNTHESIS IS CONTROVERSIAL  
 
FV and FVIII structure and function 
FV and FVIII are secreted glycoproteins that share a similar domain structure (A1-A2-B-
A3-C1-C2), with 40% amino acid sequence homology between their corresponding A 
and C domains (Figure 1-3A).42  The heavily glycosylated B-domain of FV and FVIII is 
required for efficient secretion by LMAN1 (Figure 1-3B).43,44  After secretion to the 
plasma, FV and FVIII circulate as inactive precursors that are activated by thrombin in 
order to serve as non-enzymatic cofactors for FXa and FIXa, respectively.  Numerous 
post-translational modifications of FV and FVIII occur, including cleavage of the signal 
peptide, disulfide bond formation, glycosylation, and sulfation of specific tyrosine 
residues.45   
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FV is found in the plasma and in platelet α granules as a 330 kDa single chain 
polypeptide.46  Human plasma FV concentrations are ~ 7 ug/mL.  It was previously 
reported that the human plasma and platelet FV pools are both synthesized by 
hepatocytes;47 megakaryocytes endocytose and modify FV from the plasma in order to 
form the platelet FV pool.48  In contrast, the murine plasma and platelet FV pools are 
biosynthetically distinct, with plasma FV synthesized exclusively by hepatocytes, and 
platelet FV synthesized by megakaryocytes.49   
 
Plasma FVIII is present at much lower concentration than FV (~200 ng/mL), and the full 
length protein is processed to a heterodimer comprised of an 80 kDa light chain and a 200 
kDa heavy chain.50 The FVIII light chain binds non-covalently to the amino-terminus of 
von Willebrand Factor (VWF), and this tight association between FVIII and VWF 
increases the plasma half-life of FVIII.51 
 
Conflicting evidence for the cellular source of FVIII synthesis 
Though VWF is synthesized exclusively in endothelial cells and megakaryocytes, the 
primary cellular source of FVIII biosynthesis has been controversial.  Delayed rise of 
FVIII in von Willebrand Disease (VWD) patients infused with VWF demonstrates that 
VWF and FVIII do not require synthesis in the same cell for complex formation.  Liver, 
spleen, and lung transplants have corrected hemophilia A in patients and dog models,52-60 
and dozens of conflicting reports have implicated hepatocytes, endothelial cells, 
lymphoid tissues, and renal or pulmonary epithelial cells as the source of FVIII.61-64  
Cumulatively, the majority of evidence points to either an endothelial and/or hepatocyte 
origin of FVIII synthesis.  Since LMAN1 is part of a ubiquitously expressed ER cargo 
receptor that is responsible for the efficient secretion of both FV and FVIII to the plasma, 
manipulation of LMAN1 presents a convenient molecular approach to potentially identify 
the cellular source of FVIII in vivo (see Chapter 2).  The identification of the biosynthetic 
source of FVIII may have important translational implications for the future development 
of F8 gene therapy for the treatment of hemophilia A. 
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LMAN1 BIOLOGY AND ER-TO-GOLGI PROTEIN TRANSPORT 
 
Overview of the secretory pathway  
The protein secretory pathway (Figure 1-2) is composed of a series of specialized 
compartments.  Proteins destined for secretion from the cell or for residence in secretory 
compartments (lysosomes, endosomes, plasma membrane, etc.) traffic through this 
pathway, undergoing quality-control checks and modifications.  The first critical step in 
this process is transport from the ER to the Golgi.  Correctly folded proteins in the ER 
lumen are packaged into COPII-coated vesicles for anterograde transport towards the 
Golgi.  The vesicles uncoat and fuse with one another, forming the ERGIC, and resident 
ER proteins like LMAN1 recycle back to the ER in COPI-coated retrograde vesicles to 
participate in another cycle of protein transport. 
 
Nearly 30% of all mammalian proteins travel through the secretory pathway.  The 
mechanism(s) by which cargo proteins are recruited into COPII vesicles are not clear.  
Some transmembrane cargos interact directly with the COPII coat component SEC24 via 
specific sorting signals.65  However, for soluble cargos in the ER lumen, two competing 
models have been proposed.66,67  Some secretory cargos are thought to be secreted via a 
passive bulk-flow model (no signal or receptor required); the export of amylase and 
chymotrypsinogen from the ER of pancreatic exocrine cells is reported to follow this 
model.68,69  Under the bulk-flow model, soluble proteins that do not contain a specific ER 
retention signal are gathered into transport vesicles without a concentration step, but this 
model does not explain why known ER resident proteins have been shown to be depleted 
from secretory transport vesicles.70,71  In contrast, evidence now suggests that the 
majority of soluble secretory protein cargos require a selective cargo-receptor for 
efficient recruitment into budding COPII vesicles, as demonstrated in Figure 1-4.72-78  
 
ER cargo receptors 
Approximately 8,000 proteins are trafficked through the mammalian secretory pathway, 
some of which are ubiquitously expressed, and some of which have highly specialized 
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functions in specialized secretory tissues.  The intracellular transport machinery must be 
able to efficiently and accurately sort and transport this highly variable population of 
proteins to their correct intra- or extra-cellular destinations.  Recent developments 
suggest that this sorting and transport specificity is conferred, in part, by signaling 
elements encoded within secretory proteins, and by the selective recruitment of these 
secretory cargos into COPII vesicles by cargo receptors at the ER membrane.66 
 
Much of the characterization of ER cargo receptors and their role in selective recruitment 
of cargos into COPII-coated vesicles has been performed in yeast.  A few clearly defined 
yeast cargo receptors are known to cycle between the ER and Golgi compartments, 
including the p24 proteins and Erv29p.79-81  The p24 protein Emp24p is required for 
efficient ER-export of specific secretory cargos, including the GPI-anchored protein 
Gas1p.79,82  More recent reports indicate that Erv29p acts as an export receptor for 
another selective subset of soluble secretory proteins in yeast (glycol-pro-α factor, 
carboxypeptidase Y, and proteinase A).80,83  The specific signal embedded in the glycol-
pro-α factor cargo that is recognized by Erv29p (the ER receptor) was recently identified, 
consisting of an I-L-V motif in the pro-region of glycol-pro-α factor.84  The identification 
of additional signal-receptor pairs will be critical for understanding the general 
mechanism of receptor-mediated cargo transport.  As single-celled organisms, yeast 
secrete a relatively small number of proteins outside of the cell.  In contrast, mammalian 
cells have highly complex secretory proteomes and secrete thousands of proteins outside 
of the cell.  It is therefore very surprising and intriguing that LMAN1/MCFD2 is 
currently the only known mammalian cargo-receptor in the early secretory pathway. 
 
LMAN1 is highly evolutionarily conserved, with close homologs in multiple vertebrate 
and invertebrate species, including C. elegans and D. melanogaster.  Similarly, MCFD2 
has multiple vertebrate orthologs with > 60% amino acid identity in species such as 
mouse, rat, and zebrafish.  Possible MCFD2 paralogs in invertebrate species may also 
exist.3  Importantly, the evolutionary divergence of invertebrates from vertebrates 
occurred prior to the establishment of a blood clotting system, suggesting a more general 
role for LMAN1/MCFD2 in protein secretion in addition to FV and FVIII.  This 
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evolutionary conservation of LMAN1 and MCFD2, in combination with the ubiquitous 
expression patterns of these genes, presents an exciting opportunity to explore other roles 
for LMAN1. 
 
Additional LMAN1 cargos 
In addition to FV and FVIII, which are the best characterized LMAN1 secretory cargos, 
several other proteins have been reported to rely on LMAN1 for secretion.  Utilizing a 
fluorescent protein-based protein fragment complementation assay to identify protein 
interactions in the lumen of the secretory pathway, Nyfeler et al. reported LMAN1 as an 
intracellular transport receptor for alpha-1 antitrypsin (A1AT).85  A1AT is a protease 
inhibitor belonging to the serpin superfamily, and it is of clinical relevance because 
A1AT deficiency leads to liver and lung disease.86  However, no known A1AT secretion 
defect has been observed in F5F8D patients.  In addition to FV, FVIII, and A1AT, two 
lysosomal cathepsin proteases (cathepsin C (CTSC)87 and cathepsin Z (CTSZ)88) have 
also been reported to rely on LMAN1 for ER-to-Golgi transport.  Most recently, Chen et 
al. performed a cDNA library screen from HepG2 cells via a fluorescent protein fragment 
complementation assay and identified Mac-2 binding protein (Mac-2BP) as a novel 
LMAN1-transported glycoprotein cargo.89  
 
Other proposed roles for LMAN1 
In addition to its known role in FV and FVIII secretion and F5F8D, LMAN1 has been 
implicated as a mediator of several other human diseases.  By analyzing mutation 
frequencies of genes of the cellular glycosylation machinery in microsatellite unstable 
tumors, Roeckel et al. determined that LMAN1 shows a high mutation frequency in 
microsatellite unstable colorectal cancer cell lines, carcinomas, and adenomas.90  The 
authors proposed that LMAN1 mutational inactivation may contribute to tumorigenesis in 
tumors with microsatellite instability.  In addition, LMAN1 has been reported to play a 
role (along with ERp44) in facilitating the efficient polymerization and secretion of 
immunoglobulin M (IgM) polymers in antibody-secreting cells, but no defects in IgM 
secretion have been reported in F5F8D patients.91,92  Furthermore, it was previously 
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shown that N-glycosylation of human nicastrin is required for it to interact with calnexin 
and ERGIC-53.93  Nicastrin is a component of the gamma-secretase complex, which is 
responsible for cleavage of amyloid precursor protein, Notch, and several other type 1 
transmembrane proteins.  Most recently, Klaus et al. reported an entirely novel role for 
the LMAN1 cargo receptor, demonstrating that it is required for the production of 
infectious particles from several highly pathogenic RNA virus families (arenavirus, 
coronavirus, and filovirus).94 
 
 
ANIMAL MODELS OF LMAN1 DEFICIENCY 
 
Our lab previously generated an LMAN1-deficient mouse line95 carrying a genetically 
engineered gene-trap allele (Lman1gt1) designed to disrupt the Lman1 gene.  Mice 
homozygous for this allele reproduce the human F5F8D phenotype, exhibiting low FV 
and FVIII plasma levels that are ~50% of wild-type levels.  The reduction in FV and 
FVIII levels in this mouse model are therefore less severe than the reduction of FV and 
FVIII levels in human F5F8D patients (~10-15% of normal levels).  These data suggest 
that the Lman1gt1 allele does not result in complete disruption of LMAN1 function, or 
alternatively, that F5F8D manifests differently in mice and humans.  In addition, 
Lman1gt1/gt1 mice demonstrate a partially penetrant, perinatal lethality that is specific to 
some genetic strain backgrounds.95  This unexpected lethality and the broad evolutionary 
conservation of both Lman1 and Mcfd2 suggest the hypothesis that additional critical 
LMAN1 secretory cargos remain to be discovered in addition to FV and FVIII. 
 
Mutations in the drosophila LMAN1 homolog, rhea, lead to a late embryonic recessive 
lethal phenotype.96,97  Mutant embryos develop somatic wing and muscle developmental 
defects (complete detachment of the somatic musculature from the epidermis).  In 
contrast, unpublished work performed in our lab showed that RNAi inactivation of ile-1, 
the C. elegans homolog of LMAN1, results in no detectable phenotype (B. Zhang, R. 
Ellis, and D. Ginsburg). 
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IMPORTANT REMAINING QUESTIONS FOR LMAN1 BIOLOGY 
 
The growing body of literature characterizing the LMAN1/MCFD2 cargo receptor and 
the genetic etiology of F5F8D serves as an instructive example of a rare heritable human 
disease that can provide fundamental insights into basic biologic processes.  Use of in 
vitro and in vivo models of LMAN1 and MCFD2 deficiency will enhance our 
understanding of FV and FVIII biosynthesis, and provide critical insight into the basic 
cellular process of ER-Golgi transport.  Identification of other cargo proteins relying on 
LMAN1/MCFD2 for efficient secretion should provide further understanding of this 
important pathway, and subsequently it may be possible to define the common structural 
features that mediate these interactions.  Such work may also inform the identification 
and characterization of other novel ER cargo receptors.  Further study of selective ER-to-
Golgi cargo transport may have important implications for the therapeutic modulation of 
FV and FVIII levels for the treatment of bleeding disorders or the prevention of 
thrombosis.  In addition, investigation of LMAN1/MCFD2 receptor mediated secretion 
should provide useful information relevant to the future development of safe, efficient, 
and efficacious gene therapies for hemophilia A. 
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Figure 1-1:  Structure of the LMAN1/MCFD2 receptor complex 
(A) LMAN1 is a 53-kDa type-I transmembrane protein.  Features include a signal 
sequence (SS), a carbohydrate recognition domain (CRD), a coiled-coil domain (COIL), 
a transmembrane domain (TMD), and a C-terminal cytosolic domain (CD) containing a 
di-phenylalanine (FF) ER exit motif and a di-lysine (KK) ER-retrieval signal.  The KKFF 
motif enables cycling of LMAN1 between the ER and the ER-Golgi intermediate 
compartment (ERGIC).  The 12 amino acid cytosolic domain facilitates interactions with 
the COPII coat.  Two luminal cysteines near the TMD (black arrows) form inter-
molecular disulfide bonds, which facilitate the oligomerization of LMAN1 along with 
structural determinants in the LMAN1 luminal and TM domains.  (B) MCFD2 is a 145 
amino acid 16-kDa soluble monomeric protein.  Features include a signal sequence (SS) 
for ER translocation and two calcium-binding EF-hand domains (EF-1 and EF-2) at the 
C-terminus.  Unlike LMAN1, MCFD2 does not contain an ER retrieval sequence.  The 
recycling of MCFD2 between the ER and ERGIC is dependent upon its interactions with 
LMAN1.  (C) LMAN1 and MCFD2 form a cargo receptor complex that is required for 
efficient transport of coagulation factor V (FV) and factor VIII (FVIII) from the ER to 
the Golgi.  MCFD2 interacts with LMAN1 in the ER lumen with a 1:1 stoichiometry.  A 
deficiency of either component, or a disruption of LMAN1/MCFD2 complex formation, 
results in inadequate transport and decreased secretion of FV and FVIII.  Orange ovals 
represent MCFD2, grey cylinders represent LMAN1. 
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Figure 1-2:  Model for ER-to-Golgi cargo transport by the LMAN1/MCFD2 
receptor complex 
Hexameric LMAN1 is recruited into budding COPII vesicles at the ER membrane via a 
C-terminal diphenylalanine motif (FF).  In combination with MCFD2, the 
LMAN1/MCFD2 cargo receptor complex recruits specific cargo proteins (FV, FVIII, 
A1AT, CTSC, CTSZ) into budding COPII vesicles for anterograde transport to the 
ERGIC.  COPII coat components dissociate and the vesicles fuse at the ERGIC.  
LMAN1/MCFD2 are recycled back to the ER via a di-lysine motif (KK) that facilitates 
interactions with the retrograde COPI vesicle coats.  Secretory cargos are transported 
onwards in the secretory pathway to their final intracellular (lysosomes, α-granules), 
membrane, or extracellular (plasma, extracellular matrix) destinations.  
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Figure 1-3:  Domain structures and sequence identities of FV and FVIII 
(A) FV and FVIII share a similar pro-cofactor structure containing six domains (A1-A2-
B-A3-C1-C2), with ~40% homology in the A and C domains for FV and FVIII.  The B 
domain is not homologous to other known structures and is heavily modified by N-linked 
glycosylation.  The B domains of FV and FVIII share little sequence homology with each 
other.  The A domains of FV and FVIII also share important sequence identify with the 
plasma copper-binding protein ceruloplasmin (not shown).  Branched structures represent 
N-linked glycosylation sites.  (B) The glycosylated B-domain of FVIII is required for its 
interaction with LMAN1.42   
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Figure 1-4:  COPII vesicle composition and assembly 
Proteins passing quality control checks in the ER are exported for anterograde transport 
by bulk-flow (no receptor or signal required) or by selective receptor-mediated packaging 
into COPII vesicles.  COPII vesicle formation involves the hierarchical recruitment and 
oligomerization of several coat factors at specific ER Exit Sites.  COPII-coated vesicle 
coats are composed of the small GTP-binding protein SAR1, the hetero-dimeric SEC23-
SEC24 complex, and the hetero-tetrameric SEC13-SEC31 complex.  Mammals possess 
multiple isoforms of four of the five core components (shown in color). (a) The exchange 
of GDP for GTP, catalyzed by the membrane bound guanine nucleotide exchange factor, 
SEC12, activates SAR1, which inserts into the ER membrane via an N-terminal 
amphipathic helix. (b) SAR1-GTP recruits the inner coat complex, SEC23-SEC24. (c) 
SEC24 interacts with the cytoplasmic domains of transmembrane proteins, some of 
which may serve as cargo receptors for soluble proteins. (d) The outer coat complex, 
SEC13-SEC31, polymerizes the COPII vesicle to drive budding from the ER membrane. 
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CHAPTER 2 : 
MURINE COAGULATION FACTOR VIII IS SYNTHESIZED IN 
ENDOTHELIAL CELLS 
 
Note:  Chapter 2 was accepted for publication in Blood as a regular article in March 
2014 (Authors: Lesley Everett, Audrey Cleuren, Rami Khoriaty, and David Ginsburg).  
Lesley Everett performed all experiments except for the RiboTag mouse studies, which 
were performed by Audrey Cleuren.  Rami Khoriaty assisted with blood sample 
collection and analysis.  Submission date: February 8, 2014.   
 
 
INTRODUCTION 
 
Plasma coagulation factor VIII (FVIII) is tightly associated with von Willebrand Factor 
(VWF).  Though it is well established that VWF is synthesized exclusively in endothelial 
cells and megakaryocytes, the cellular source of FVIII has been debated for decades.  The 
delayed rise of FVIII in von Willebrand Disease patients infused with VWF demonstrates 
that VWF and FVIII do not require synthesis in the same cell for complex formation.98  
Dozens of conflicting reports have implicated numerous cell and tissue types as the 
source of FVIII, though the majority of evidence points to either an endothelial and/or 
hepatocyte origin of FVIII synthesis.61-63    
 
Multiple curative organ transplantation studies in hemophilia A patients and experimental 
dog models have shown that the liver contributes significantly to FVIII biosynthesis,52-55 
though the failure of FVIII levels in hemophilia A liver transplant recipients to respond to 
desmopressin suggested FVIII localization to a different compartment than VWF.99  As 
early as 1971, Webster et al. demonstrated extra-hepatic FVIII synthesis by showing that 
FVIII synthesis was maintained after replacing the livers of normal dog recipients with 
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hemophilic livers.56  Similarly, extra-hepatic FVIII production was shown in humans 
after transplantation of a hemophilia A donor liver into a non-hemophilic recipient.57  
Spleen and lung transplantation has been shown to restore FVIII plasma levels in several 
animal models of hemophilia,58-60,64 and FVIII production also has been documented by 
human purified microvascular endothelial cells from lung in vitro.100   
 
Immunoradiometric assays localized FVIII antigen to guinea pig liver, spleen, lung, 
kidney, and to isolated hepatocytes,61,101 and to human lymph nodes, lung, liver, and 
spleen,102 whereas microscopy studies suggested synthesis in human hepatocytes62 or 
human liver sinusoidal endothelial cells (LSECs).103,104  F8 mRNA transcripts have been 
detected in purified murine LSECs and hepatocytes at comparable levels, but not in 
Kupffer cells,63 and by others in human spleen, lymph nodes, kidney, and in isolated 
hepatocytes, but not in white blood cells or cultured umbilical vein endothelial cells.61  
F8 mRNA transcripts have also been shown to be synthesized in hemophilia A mouse 
livers by hepatocytes and LSECs that were derived from transplanted wild-type bone 
marrow progenitor cells.105   
 
We took advantage of a genetically modified mouse model that is deficient for LMAN1 
(Lectin, mannose-binding protein 1, also known as ERGIC-53).  LMAN1 is part of a 
ubiquitously expressed cargo receptor that cycles between the endoplasmic reticulum 
(ER) and the ER-Golgi intermediate compartment (ERGIC) in the early secretory 
pathway.  LMAN1 is required for the efficient secretion of FVIII as well as coagulation 
factor V (FV) to the plasma.  Mutations in LMAN1 cause an autosomal recessive bleeding 
disorder known as combined deficiency of coagulation factors V and VIII (F5F8D).  
Although FV and FVIII are synthesized at markedly different levels (human plasma FV 
~7.0 ug/mL, and FVIII ~0.2 ug/mL) and potentially in different tissues, loss of the 
LMAN1 cargo receptor in F5F8D leads to parallel reduction of both of these factors to 
~10-15% of normal levels.3,4 
 
We previously reported a genetically engineered mouse carrying a gene-trap interruption 
of the Lman1 gene.95  Mice homozygous for this gene-trap allele (Lman1gt1/gt1) exhibit 
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reduced FV and FVIII levels that are ~50% of normal, in contrast to the ~10-15% levels 
in human patients with F5F8D.  As expected, this modest reduction in FV and FVIII 
results in a much milder phenotype than reported for hemophilia A mice carrying a F8 
gene-targeted allele leading to complete absence of FVIII.106  We now describe a second, 
independent conditional Lman1 allele, and analysis of mice with LMAN1 deficiency 
induced specifically in the hepatocyte or endothelial cell compartments.  Deletion of 
Lman1 only in hepatocytes results in reduced FV, but normal plasma FVIII, whereas 
endothelial Lman1 deletion reduces FVIII but not FV plasma levels.  In addition, analysis 
of purified, endothelial-specific polysomes by qRT-PCR confirms F8 mRNA expression 
in endothelial cells (relative to total tissue lysates), with considerable heterogeneity in the 
level of F8 mRNA expression across different vascular beds. 
 
 
MATERIALS AND METHODS 
 
Lman1 conditional knockout mice 
Embryonic stem (ES) cell clone B06 (C57BL/6 genetic background) carrying a 
conditional Lman1 gene-trap allele (Lman1cgt, also known as Lman1tm1a(KOMP)Wtsi) with a 
gene-trap insertion into Lman1 intron 1 and loxP sites flanking exons 2-3 was obtained 
from the Knockout Mouse Project (KOMP; www.komp.org) (Figure 2-1A).  Correct 
targeting of the conditional gene-trap construct was confirmed by long-range PCR at both 
the 5’ and 3’ ends of the targeted allele with Phusion Hot Start High-Fidelity DNA 
Polymerase (Finnzymes) (Supplementary Figure 2-1A) using the PCR primers listed in 
Supplementary Table 2-1.  The ES clone was expanded and then injected into C57BL/6J 
blastocysts at the University of Michigan Transgenic Mouse Core.  Germ-line 
transmission was achieved by mating male chimeric founders with C57BL/6J albino 
female mice (B6(Cg)-Tyrc-2J/J; stock no. 000058, The Jackson Laboratory). The 
resulting germ-line transmitted Lman1cgt allele was continuously backcrossed and 
maintained on a C57BL/6J genetic background, as were all subsequent distinct alleles 
derived from Lman1cgt.  Primer trio LMAN1 C/D/E was used to distinguish between the 
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wild-type Lman1+ allele and the targeted conditional Lman1cgt allele (Figure 2-1B).  
Primer set LMAN1 A/B also distinguishes between the Lman1+ allele and the Lman1cgt 
allele (Figure 2-1C).  Genotyping for all animals reported in this study was performed 
with mouse tail clip DNA using Go-Taq Green Master Mix (Promega) and the relevant 
primers listed in Supplementary Table 2-1, with the resulting PCR products resolved by 
2% agarose gel electrophoresis.  The expected PCR amplicon sizes for all Lman1 alleles 
generated with primer sets C/D/E and A/B/C are listed in Table 2-1.   
 
Transgenic mice (C57BL/6J background) carrying Flpe (flippase) recombinase driven by 
an actin promoter were obtained from The Jackson Laboratory (B6;SJL-
Tg(ACTFLPe)9205Dym/J; stock no. 003800).  Intercrosses of Lman1cgt/+ mice and Flpe 
recombinase transgenic mice generated the Lman1fl allele (also known as 
Lman1tm1c(KOMP)Wsti) (Figure 2-1A).  Transgenic Tek-Cre+ (Tie2-Cre) recombinase mice 
(B6.Cg-Tg(Tek-cre)12Flv/J; stock no. 004128) and Alb-Cre+ recombinase mice (B6.Cg-
Tg(Alb-cre)21Mgn/J; stock no. 003574) were obtained from The Jackson Laboratory.  
Primer trio LMAN1 A/B/C was used to distinguish between the Lman1+ allele and the 
Lman1fl and Lman1- alleles derived from Lman1cgt (Figure 2-1C) for the identification of 
conditional knockout Lman1 mice, and Alb-Cre or Tek-Cre primers (listed in 
Supplementary Table 2-1) were used to determine the Cre genotype.  The Alb-Cre 
Fwd/Rev primer pair generates a single 207 bp PCR amplicon.  The Tek-Cre multiplex 
primer trio generates an internal control 200 bp PCR product from the endogenous Tek 
gene, and a 579 bp PCR product from the Tek-Cre transgene.  Tek-Cre driven 
recombinase activity results in the deletion of loxP flanked target sequences in 
endothelial cells (of all tissues) and hematopoietic cells, but also to a lesser extent in the 
germline.  Only male Lman1fl/+, Tek-Cre+ mice were crossed with female Lman1fl/fl mice 
to generate Lman1fl/fl, Tek-Cre+ offspring, since the Tek-Cre recombinase activity occurs 
at a lower frequency in the male germline than in the female germline.107  
 
All animals were housed according to the guidelines of the University of Michigan Unit 
of Laboratory Animal Medicine.  The University of Michigan’s University Committee on 
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the Use and Care of Animals approved all animal protocols in this study under protocol 
number 08571. 
 
Western blot antibodies 
Antibodies used in Western blot experiments were: a monoclonal antibody against human 
β-actin (Santa Cruz Biotechnology), a monoclonal antibody against the RalA GTPase 
(Sigma-Aldrich), a goat-anti-mouse IgG HRP antibody, a polyclonal antibody against 
LMAN1 (Sigma-Aldrich), and a polyclonal rabbit antibody against the heavy chain of 
murine FV.108  FV antigen levels in plasma and platelets were assessed by Western blot 
analysis using the FV antibody.  
 
Measurement of FV and FVIII levels 
Blood was collected into 4% sodium citrate solution (9:1) (Sigma-Aldrich) via inferior 
vena cava puncture essentially as previously described,109 under pentobarbital anesthesia 
(Nembutal Sodium Solution) with a 1 mL syringe.  Platelet poor plasma was isolated as 
previously described,110 snap frozen, and stored at -80°C.  Platelet rich plasma and 
platelet pellets were isolated and processed as follows: 2 mL of room temperature 
Buffered Saline Glucose Citrate (BSGC) (129 mM NaCl, 13.6 mM Na3 citrate, 11.1 mM 
glucose, 1.6 mM KH2PO4, 8.6 mM NaH2PO4, pH 7.3) were placed in a 5 mL 
polypropylene tube, to which was added 1-1.5 mL of whole blood.  BSGC was added to a 
final volume of 4 mL, and then gently mixed by inversion.  The tubes were centrifuged at 
180 x g for 10 minutes at room temperature.  The supernatant (semi-platelet rich plasma) 
was removed and subjected to a platelet count on an Advia 120 Automated Hematology 
Analyzer (Siemens), and the number of platelets was normalized between samples before 
centrifuging in fresh tubes at 700 x g for 10 minutes.  Platelet pellets were lysed with 
Triton-X 100 on ice (final concentration 0.2%) for 30 minutes and frozen as previously 
described.95  Plasma and platelet samples from previously described F5-/- mice carrying 
either a platelet- or plasma- specific F5 transgene,49 respectively, were used as 
experimental controls. 
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Plasma FV and FVIII activity levels were determined in prothrombin time (PT) and 
partial thromboplastin time (PTT) based assays, respectively.  Individual mouse plasma 
samples were mixed with human plasma deficient for the respective factor (George King) 
and analyzed on a KC-4 Coagulation Analyzer (Sigma-Aldrich).  A pooled C57BL/6J 
plasma stock was diluted into human FV or FVIII deficient plasma (George King) to 
generate a reference standard curve.  
 
RiboTag mice 
RiboTag mice111 (B6.129-Rpl22tm1.1Psam/J) were a kind gift from Dr. Paul Amieux 
(University of Washington) and were also obtained from The Jackson Laboratory (stock 
no. 011029).  Genotyping primers for the RiboTag mice are listed in Supplementary 
Table 2-1.  RiboTag mice (Rpl22HA/HA) in this study are homozygous for a modified 
Rpl22 gene (ribosomal protein L22) that contains both a wild-type exon 4 flanked by 
loxP sites, as well as an alternate hemagglutinin (HA)-tagged exon 4 sequence. 
 
RNA isolation 
Mice were anesthetized followed by intracardiac perfusion with 12 mL of 100 ug/mL 
cyclohexamide (Sigma) in PBS, after which tissues were isolated and snap frozen in 
liquid nitrogen.  Immunoprecipitation of endothelial cell-specific polysomes (and bound 
mRNA) from whole liver, kidney, brain, and heart lysates was performed essentially as 
previously described, with minor modifications.111   Frozen tissues were pulverized and 
the resulting powders were transferred to tubes containing polysome buffer (50 mM Tris, 
pH 7.5, 100 mM KCl, 12 mM MgCl2, 1% Nonidet P-40, 1 mM DTT, 200 U/mL 
Promega RNasin, 1 mg/mL heparin, 100 ug/mL cycloheximide, Sigma protease inhibitor 
mixture).  Cleared lysate was incubated with a purified mouse monoclonal antibody 
against the hemagglutinin tag (HA.11 clone 16B12, Covance, 3 ug per sample) for 1 hour 
with rotation at 4°C.  Protein G magnetic beads (New England Biolabs) equilibrated in 
polysome buffer were added for an additional 30-minute rotated incubation at 4°C.  The 
beads were washed in high salt buffer (50 mM Tris, pH 7.5, 300 mM KCl, 12 mM 
MgCl2, 1% Nonidet P-40, 1 mM DTT, 100 ug/mL cycloheximide), and ribosome-
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associated mRNA was subsequently eluted from the beads by adding Qiagen buffer RLT 
supplemented with 2-mercapto-ethanol (1% v/v).  Total RNA was isolated from the 
whole tissue lysates (input) and immunoprecipitated polyribosome samples with the 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol, and DNase 
treatment was performed on column (Qiagen).  RNA samples were quantified on a 
spectrophotometer (Nanodrop) and the integrity of the RNA was assessed by gel 
electrophoresis.  Total RNA from whole blood of C57BL/6J mice was extracted with 
Trizol LS and purified on RNeasy spin columns (Qiagen).   
 
cDNA conversion and qPCR analysis 
Total mRNA (100 ng) from input lysates and HA-tagged polysome samples was 
converted to cDNA with the Superscript First-Strand system (Invitrogen) and oligoDT 
primers.  Gene-specific primers (Supplementary Table 2-1) were designed with Primer 
Express Software (Applied Biosystems) and qRT-PCR was executed with SYBR-Green 
RT-PCR Master Mix (Applied Biosystems) on a 7900HT Fast Real-Time PCR machine 
(Applied Biosystems).  Data were analyzed using the comparative threshold cycle 
method112 with Rpl37 (Ribosomal protein L37), Rpl38 (Ribosomal protein L38), and 
Eif3e (eukaryotic translation initiation factor 3, subunit E) as internal controls,113 and the 
ΔCt value of the bead elution was related to the ΔCt value (Ct value of sequence of 
interest – Ct value of reference sequence) of its respective total tissue lysate to determine 
the fold-change.  One microgram of mRNA from whole blood was used for subsequent 
cDNA conversion with oligoDT primers. 
 
Statistical analysis 
A chi-squared test was used to evaluate for statistical deviation from expected Mendelian 
ratios for the genotypes of offspring from matings between Lman1fl/fl mice and Lman1fl/+, 
Cre+ mice.  Analysis of the FV and FVIII activity data was performed using the Student’s 
t-test comparing pooled levels from Lman1fl/fl and Lman1fl/+ (control) mice relative to 
levels from the other experimental genotypes (Lman1fl/fl, Cre+ and Lman1fl/+, Cre+).  To 
evaluate the qPCR data with respect to enrichment or depletion in the endothelial cell-
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fraction relative to the whole tissue lysate, a paired t-test was performed.  A Student’s t-
test was used to analyze the qPCR data for whole blood relative to whole tissue lysates.  
A p-value < 0.05 was considered to be statistically significant for all analyses.  
 
 
RESULTS 
 
FVIII is synthesized in murine endothelial cells 
Long-range PCR confirmed the correct genomic targeting of the Lman1cgt KOMP 
targeting construct (Supplementary Figure 2-1B).  Lman1cgt/+ mice were crossed to Flpe 
recombinase transgenic mice to excise the gene-trap cassette, generating the Lman1fl 
allele in which exons 2-3 are flanked by loxP sites, but no other gene-trap sequence is 
retained (Figure 2-1A). The Lman1fl allele may be converted to the null Lman1- allele in a 
conditional manner by tissue-specific Cre-mediated excision of exons 2 and 3.  
Heterozygous Lman1fl/+ mice were crossed with male transgenic Tek-Cre+ (Tie2-Cre) 
mice that carry the Cre recombinase gene driven by the Tek promoter to generate 
Lman1fl/+, Tek-Cre+ mice with a single Tek-Cre allele.  To delete Lman1 in endothelial 
cells of all tissues, Lman1fl/+, Tek-Cre+ mice were subsequently crossed to Lman1fl/fl mice 
to generate Lman1fl/fl, Tek-Cre+ endothelium-specific knockout mice.  The same general 
mating scheme was used to generate hepatocyte-specific Lman1 knockout mice by 
utilizing an Alb-Cre recombinase.  Lman1fl/fl, Tek-Cre+ mice (endothelial-knockout) and 
Lman1fl/fl, Alb-Cre+ (hepatocyte-knockout) mice are viable and were observed in the 
expected Mendelian ratios (Table 2-2).  As demonstrated by PCR analysis of genomic 
DNA isolated from an Lman1fl/fl, Alb-Cre+ mouse tail snip and liver tissue, the 
conversion of the Lman1fl allele to the Lman1- null allele by genetic excision of Lman1 
exons 2 and 3 was very efficient and specific to the liver (Figure 2-1C).  Similarly, 
Western blot analysis of LMAN1 levels in multiple tissues harvested from wild-type 
C57BL/6J mice and Lman1fl/fl, Alb-Cre+ mice confirmed efficient loss of LMAN1 
expression in the liver of Lman1fl/fl, Alb-Cre+ mice (Figure 2-1D).  The equivalent levels 
of LMAN1 in other tissues of Lman1fl/fl mice compared to wild-type mice confirmed 
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normal LMAN1 expression from the Lman1fl allele in the absence of Cre recombinase 
(Figure 2-1D).  FV and FVIII activity levels for both Lman1fl/+, Tek-Cre+  and Lman1fl/+, 
Alb-Cre+ mice (heterozygous conditional knockout mice) were indistinguishable from 
control animals (Figure 2-2A and Figure 2-2B), consistent with the autosomal recessive 
inheritance of F5F8D, and with previous results in Lman1gt1/+ mice.95  Lman1fl/fl and 
Lman1fl/+ mice were pooled together as controls for subsequent experiments. 
 
As expected from the known synthesis of plasma FV in hepatocytes,49 Lman1fl/fl, Alb-
Cre+ mice demonstrate significant reduction of plasma FV activity relative to Lman1fl/fl 
and Lman1fl/+ control mice (48.3% vs. 96.8%, p < 1.5 x 10-10) (Figure 2-2A), with 
consistent reductions in plasma FV antigen level also observed by Western blotting 
(Figure 2-3A).  Plasma FV activity in Lman1fl/fl, Alb-Cre+ mice was indistinguishable 
from Lman1gt1/gt1 mice (p > 0.5, Figure 2-2A), suggesting highly efficient excision in 
hepatocytes, as directed by the Alb-Cre transgene.  In contrast, plasma FVIII levels in 
Lman1fl/fl, Alb-Cre+ mice were indistinguishable from controls (90.2% vs. 97.5%, p > 
0.12) (Figure 2-2B).  These data demonstrate that hepatocyte synthesis does not 
contribute significantly to the plasma FVIII pool in the mouse.  The Lman1fl/fl, Tek-Cre+ 
mice exhibit normal plasma FV activity relative to Lman1fl/fl and Lman1fl/+ control mice 
(99.8% vs. 96.8%, p > 0.5) (Figure 2-2A).  In contrast, FVIII activity levels in Lman1fl/fl, 
Tek-Cre+ mice were markedly reduced (52.8% vs. 97.5%, p < 1.7 x 10-8) and were 
indistinguishable from the levels previously reported in Lman1gt1/gt1 null mice (52.8% vs. 
47.9%, p > 0.30)  (Figure 2-2B).  These results suggest that endothelial cells are the 
primary biosynthetic source of FVIII in vivo. 
 
The murine plasma and platelet FV pools are biosynthetically distinct and are derived 
from synthesis in hepatocytes and megakaryocytes, respectively.114  Consistent with these 
previous reports, platelet FV antigen, as assessed by Western blotting, appears roughly 
equivalent to control mice in Lman1fl/fl, Alb-Cre+ mice, with a modest reduction in 
Lman1fl/fl, Tek-Cre+ mice, (Figure 2-3B), consistent with the known expression of Tek-
Cre in megakaryocytes.115 
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F8 mRNA is localized to endothelial cells and not hepatocytes 
The previously reported RiboTag mouse111 was used to isolate endothelial cell-specific 
mRNA for qPCR analysis from a number of different murine tissues.  In the absence of 
Cre-recombinase, RiboTag mice ubiquitously express the wild-type RPL22 ribosomal 
protein in all cell types.  However, in the presence of Cre-recombinase, RPL22 is fused to 
a hemagglutinin-tag, which can be used to selectively immunoprecipitate polyribosomes 
derived only from cells expressing Cre.111  Mice homozygous for the RiboTag allele and 
hemizygous for the Tek-Cre transgene were generated, which should result in expression 
of the RPL22-HA fusion protein only in endothelial (and hematopoietic) cells. 
 
qPCR analyses of endothelial cell mRNA isolated from unfractionated liver lysates from 
RiboTag, Tek-Cre+ mice (n =4) (Figure 2-4A;  Supplementary Table 2-2) demonstrated 
depletion (5-10 fold) of transcripts from several known hepatocyte-specific genes, 
including Albumin (Alb), prothrombin (F2), coagulation factor V (F5), coagulation 
factor VII (F7), and coagulation factor X (F10).  In contrast, a 15-22 fold enrichment was 
observed for gene transcripts that are known to be endothelial-specific, including 
Cadherin 5 (Cdh5), TEK tyrosine kinase (Tek), Vascular cell adhesion molecule 1 
(Vcam1), and von Willebrand factor (Vwf).   
 
Similarly, endothelial cell mRNA from kidney (Figure 2-4B; Supplementary Table 2-2), 
brain (Figure 2-4C; Supplementary Table 2-2), and heart (Figure 2-4D; Supplementary 
Table 2-2) prepared from the same four RiboTag, Tek-Cre+ mice showed 10-50 fold 
depletion of corresponding tissue specific non-endothelial cell genes, and 4-20 fold 
enrichment of endothelial cell-specific genes (Cdh5, Tek, Vcam1, and Vwf). 
 
qPCR analysis of F8 mRNA levels revealed an unexpected variation in the level of F8 
expression across these vascular beds.  F8 mRNA transcripts were highly enriched 
(relative to total tissue lysate) in liver endothelial cells (16.5 fold, p < 2.2 x 10-4), 
comparable to that of known endothelial-specific genes.  F8 transcripts were also 
enriched in kidney endothelial cells (7.4 fold, p < 1.6 x 10-3).  However, no F8 mRNA 
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enrichment was observed in the endothelial cells of brain (0.25 fold, p > 0.1) or heart 
(0.67 fold, p > 0.15).             
 
Circulating peripheral blood cells do not express F8 mRNA 
Since Tek-Cre is also expressed in hematopoietic cells,115 qRT-PCR was performed on 
whole blood to exclude contaminating blood as the source of the enriched F8 mRNA in 
RiboTag, Tek-Cre+ tissues.  F8 mRNA in the blood was detected at < 2% of the levels in 
liver and kidney, with normalization to internal control genes Rpl37, Rpl38, and Eif3e 
(Table 2-3). Thus, peripheral blood cell mRNA can be excluded as the source of the F8 
mRNA signal in RiboTag, Tek-Cre+ mouse tissues.  The enrichment of mRNA 
transcripts for Vwf and F5 in whole blood mRNA is consistent with the known expression 
patterns of these genes in murine megakaryocytes/platelets.49,116,117 
 
 
DISCUSSION 
 
The in vivo biosynthetic origin of FVIII has been controversial for decades.52-57,59-63,100-105  
We took advantage of the dependence of efficient FV and FVIII secretion on LMAN1 to 
examine the cellular biosynthetic source of each protein in vivo.  While both the human 
plasma and platelet FV pools are produced by hepatocytes,47 murine plasma FV is 
synthesized exclusively in hepatocytes, and murine platelet FV in megakaryocytes.49,114  
In the absence of LMAN1, FV levels are reduced in both plasma and platelets in humans 
and mice.4,41,95   
 
Consistent with these previous data, we observed that mice with Lman1 specifically 
deleted in the hepatocytes exhibit low plasma FV and normal platelet FV, while Lman1 
deletion in the hematopoietic compartment results in low platelet FV and normal plasma 
FV.  Our finding of normal FVIII in mice with hepatocyte-specific knockout of Lman1 
excludes the hepatocyte as a major source of FVIII production in vivo.  Conversely, the 
observation that endothelial deletion of Lman1 results in reduced FVIII levels that are 
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comparable to the levels in LMAN1 null mice (Figure 2-2B) indicates that high level, 
tissue-specific Lman1 excision was achieved with the Tek-Cre recombinase, and suggests 
that the endothelial cell is the primary source of FVIII biosynthesis in vivo.   
 
The Tek-Cre used for specific targeting to the endothelium is known to be expressed both 
in the endothelial and hematopoietic compartments.118,119  The absence of F8 mRNA 
enrichment in peripheral blood of wild-type C57BL/6J mice excludes trapped peripheral 
blood cells as the source for the FVIII endothelial cell signal, as does the absence of F8 
mRNA enrichment in the brain or heart (Figure 4).  The lack of F8 mRNA in the blood is 
consistent with a recent clinical report of allogeneic bone marrow transplantation (BMT) 
in a child with severe aplastic anemia and hemophilia A.  The child’s FVIII levels and 
coagulation test results remained essentially unchanged from his pre-transplantation 
values when measured four months after BMT,120 indicating that the bone marrow is not 
an important source of FVIII synthesis in vivo.   
 
Examination of affinity-selected endothelial cell mRNA from actively translating 
ribosomes isolated from multiple tissues confirmed endothelial FVIII biosynthesis in 
vivo.  However, the levels of F8 mRNA observed in the endothelial cells of liver, kidney, 
brain, and heart tissues revealed surprising variation across these vascular beds, with the 
highest levels of expression in liver endothelial cells, intermediate levels in kidney, and 
no detectable enrichment of F8 mRNA transcripts in brain or heart endothelial cells. 
 
Taken together, these data demonstrate that endothelial cells from multiple (but not all) 
tissues and vascular beds contribute to the plasma FVIII pool in the mouse, with a large 
contribution from hepatic endothelial cells.  These results account for the successful 
reversal of hemophilia A by liver transplantation, and presumably also by lung and spleen 
transplantation.52-54,59,60  These results are also consistent with the maintenance of normal 
FVIII levels in patients with parenchymal liver disease in whom the endothelium may 
still be intact.121-123  The variable levels of endothelial cell mRNA enrichment across 
tissues likely reflects differences in mRNA expression profiles and the relative ratio of 
endothelial to parenchymal cells in different vascular beds.124-126  Though the functional 
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significance of this heterogeneity in FVIII endothelial production is unknown, it could 
reflect variation in local hemostatic demand across different vascular beds. 
 
Our data are also consistent with several recent publications reporting the relative 
contributions of hepatocytes and endothelial cells to the plasma FVIII pool.  
Transplantation of unfractionated liver cells (a mixture of hepatocytes, LSECs, Kupffer 
cells, and hepatic stellate cells) into the peritoneal cavity of hemophilia A mice corrected 
the disease, but transplantation of a hepatocyte-enriched fraction alone had no effect.127  
Similarly, transplanted normal endothelial cells are able to repopulate the liver 
endothelium and correct the bleeding phenotype of hemophilia A mice.128  In addition, 
FVIII activity levels were found to be 10- to 100-fold higher in human LSECs than in 
hepatocytes separated by flow cytometry cell sorting.129  Nonetheless, other studies have 
detected FVIII in human hepatocytes,52-55,130 and differences in the pathway for FVIII 
production between humans and mice cannot be excluded.     
 
A growing body of evidence suggests extensive heterogeneity among endothelial cells in 
vivo.131  For example, Vwf expression varies widely across different endothelial beds, 
with different tissue micro-environmental factors regulating its transcription.132,133  
Similarly, the expression of dozens to hundreds of genes may vary among different 
specialized vascular beds.134  While we observed modest variation in the expression 
levels of Vwf and 3 other endothelial-specific genes in our studies of lung, kidney, heart, 
and brain endothelial cells, we observed large differences in F8 gene expression amongst 
these four tissues.  F8 mRNA transcripts were most highly enriched in hepatic 
endothelial cells, with intermediate enrichment in kidney endothelial cells and little to no 
enrichment in the endothelial cells of heart or brain.  Our results are consistent with 
recent transcriptional profiling of tissue-specific endothelial cell populations isolated by 
flow sorting, where F8 mRNA transcripts were detected in endothelial cells from liver 
and glomeruli, but not in the testis, spleen, muscle, brain, lung, heart, or bone marrow.124  
This heterogeneity of endothelial cell gene expression has important implications, not 
only for FVIII biosynthesis, but also for regulation of other tissue-specific endothelial 
cell functions.135,136  The finding that F8 and Vwf are both highly expressed in endothelial 
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cells likely confers a regulatory mechanism for FVIII biosynthesis, consistent with 
previous reports that the coexpression of F8 and Vwf in vitro result in increased stable 
accumulation of FVIII activity.51  Finally, the establishment of endothelial cells as the 
primary site of FVIII biosynthesis also has important implications for the treatment of 
hemophilia A, particularly for gene-targeting approaches directed specifically to 
endothelial cells.137-139 
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Table 2-1:  Expected PCR amplicon size (bp) for KOMP Lman1 alleles 
Primer Set Lman1+ Lman1cgt Lman1fl Lman1- 
C/D/E 434 565 591 (no product) 
A/B/C 444 508 508 635 
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Table 2-2:  Generation of Lman1 conditional knockout mice 
Crosses Genotype Distribution at 3 weeks p-value (χ2) 
 Lman1fl/+, 
Cre- 
Lman1fl/+, 
Cre+ 
Lman1fl/fl, 
Cre- 
Lman1fl/fl, 
Cre+  
 
Expected % 25% 25% 25% 25%  
Lman1fl/fl x 
Lman1fl/+, Alb-Cre+ 24% (17) 25% (18) 19% (14) 32% (23) 0.5 (n.s.) 
Lman1fl/fl x 
Lman1fl/+, Tek-Cre+ 19% (16) 28% (23) 26.5% (22) 26.5% (22) 0.7 (n.s.) 
The chi-squared test (df = 3) was based upon an expected genotype ratio of 3:1, with 
Lman1fl/fl/Cre+ mice expected to represent 25% of the offspring from each mating, and all other 
genotypes cumulatively accounting for 75% of offspring. 
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Table 2-3:  Gene expression average fold-change in the whole blood mRNA relative 
to total liver and kidney lysates (input) 
Whole blood vs. liver lysate 
Gene Expression Fold-change ± SEM Range p-value 
Cdh5 Endothelial 0.19 ± 0.02 0.17 – 0.22 < 3.5 x 10-2 
Tek Endothelial 0.04 ± 0.01 0.034 – 0.046 < 2.0 x 10-3 
Vcam1 Endothelial 0.001 ± 0.004 0.001 – 0.009 < 6.0 x 10-3 
Vwf Endothelial/Megakaryocyte 113.40 ± 7.09 106.6 – 120.7 < 3.0 x 10-6 
F5 Hepatic/Megakaryocyte 1.31 ± 0.06 1.25 – 1.36 > 0.3 
F8 ? 0.01 ± 0.01 0.007 – 0.012 < 1.0 x 10-4 
     
Whole blood vs. kidney lysate 
Gene Expression Fold-change ± SEM Range p-value 
Cdh5 Endothelial 0.08 ± 0.01 0.074 – 0.095 < 7.4 x 10-5 
Tek Endothelial 0.002 ± 0.001 0.007 – 0.010 < 2.1 x 10-5 
Vcam1 Endothelial 0.003 ± 0.004 0.001 – 0.009 < 3.2 x 10-3 
Vwf Endothelial/Megakaryocyte 248.92 ± 15.56 233.2 – 264.9 < 3.3 x 10-9 
F5 Hepatic/Megakaryocyte 73.41 ± 3.15 70.3 – 76.6 < 1.5 x 10-5 
F8 ? 0.02 ± 0.01 0.011 – 0.029 < 1.5 x 10-4 
To evaluate the potential contribution of blood contamination to transcript levels of endothelial-
specific genes, the tissue lysates of either the kidney or liver samples were set as a reference and 
the ΔCt values of individual blood samples (n=4) were related to the mean ΔCt of the reference 
group. 
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Supplementary Table 2-1:  Primer sequences 
Primer 5’ à 3’  Sequence 
Genotyping Primers 
Lman1 primer A GGCTTTCTTGACACCTTCAATTTAA 
Lman1 primer B CCAAGTGAAGGGAAGACCATCAAGC 
Lman1 primer C GACCCCTAGTGACGGGTTCTTGTC 
Lman1 primer D CACTGAGTCTCTGGCATCTCCCCT 
Lman1 primer E CCCACAAATTAAATGTCAAGGACA 
Flpe transgene Fwd GGTCCAACTGCAGCCCAAGCTTCC 
Flpe transgene Rev GTGGATCGATCCTACCCCTTGCG 
Alb-Cre transgene Fwd GAAAATGCTTCTGTCCGTTTGC 
Alb-Cre transgene Rev ATTGCTGTCACTTGGTCGTGGC 
Tek Fwd CCCTGTGCTCAGACAGAAATGAGA 
Tek Rev TAAGCCGGCTAAAGAGTCCA 
Tek-Cre transgene Rev CGCATAACCAGTGAAACAGCATTG 
RiboTag Fwd GGGAGGCTTGCTGGATATG 
RiboTag Rev TTTCCAGACACAGGCTAAGTACAC 
qPCR Primers  
Rpl37 Fwd CGGGACTGGTCGGATGAG 
Rpl37 Rev TCACGGAATCCATGTCTGAATC 
Rpl38 Fwd CGCCATGCCTCGGAAA 
Rpl38 Rev CCGCCGGGCTGTCAG 
Eif3e Fwd GGTTGGATGCCAAGATTGATTC 
Eif3e Rev GGGCGAGACTGCATTGTTG 
Cdh5 Fwd AGCGCAGCATCGGGTACT 
Cdh5 Rev TCGGAAGAATTGGCCTCTGT 
Vcam1 Fwd GGCAGAGTGTACAGCCTCTTTATG 
Vcam1 Rev GCTGACCCAGATGGTGGTTT 
Vwf Fwd AGCTGTCAGCCAGGTTTTTCTT 
Vwf Rev GCAGAGGGCAGGCACCTT 
Tek Fwd CTATCGGACTCCCTCCTCCAA 
Tek Rev TCAAATTTAGAGCTGTCTGGCTTTT 
Alb Fwd GGACCAGGAAGTGTGCAAGAA 
Alb Rev CAAGAACGTGCCCAGGAAGA 
F2 Fwd GGACGCTGAGAAGGGTATCG 
F2 Rev CCCCACACAGCAGCTCTTG 
F5 Fwd CCAGGTAGCTGGCATGCAA 
F5 Rev CCATTGGCATCTTACACTCTTTGT 
F7 Fwd CTGTCATGAGGACTACACGCTACA 
F7 Rev CACGGGTACTCAACTTTTGGTTT 
F8 Fwd CTTCACCTCCAGGGAAGGACTA 
F8 Rev TCCACTTGCAACCATTGTTTTG   
F10 Fwd GTGGCCGGGAATGCAA 
F10 Rev AACCCTTCATTGTCTTCGTTAATGA 
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Aqp2 Fwd CCCTGGCTCCAGCAGTTG 
Aqp2 Rev CGATCCAGAAGACCCAGTGATC 
Cdh16 Fwd TGGAGGCCCAAGACACAGA 
Cdh16 Rev TGGATCACAACAGTGGCAGAA 
Umod Fwd CAGCCTGAAGACCTCCCTACA 
Umod Rev TCCCACCCAAGCTGATGTTC 
Penk Fwd TGCAGCTACCGCCTGGTT 
Penk Rev CAGTGTGCACGCCAGGAA 
Tac1 Fwd GATGCTGATTCCTCAGTTGAAAAA 
Tac1 Rev GATCTGGCCATGTCCATAAAGAG 
Fabp3 Fwd AGTCACTCGGTGTGGGCTTT 
Fabp3 Rev ATGATGGTAGTAGGCTTGGTCATG 
Myh6 Fwd CCCTCAATGACTTCACCACACA 
Myh6 Rev CTAGCCAACTCCCCGTTCTCT 
Tnnt2 Fwd GAAGTTCGACCTGCAGGAAAA 
Tnnt2 Rev TTCGCAGAACGTTGATTTCG 
Genes:  Rpl37, Ribosomal protein L37; Rpl38, Ribosomal protein L38; Eif3e, Eukaryotic 
translation initiation factor3, subunit E; Cdh5, Cadherin 5, type 2; Vcam1, Vascular cell 
adhesion molecule 1; Vwf, von Willebrand factor; Tek, TEK tyrosine kinase, endothelial; 
Alb, Albumin; F2, Prothrombin; F5, Coagulation factor V; F7, Coagulation factor VII; 
F8, Coagulation factor VIII; F10, Coagulation factor X; Aqp2, Aquaporin 2; Cdh16, 
Cadherin 16; Umod, Uromodulin; Penk, Preproenkephalin; Tac1, Tachykinin, precursor 
1; Fabp3, Fatty acid binding protein 3, muscle and heart; Myh6, Myosin, heavy 
polypeptide 6, cardiac muscle, alpha; Tnnt2, Troponin T type 2 (cardiac). 
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Supplementary Table 2-2:  Gene expression average fold-change in the endothelial 
cell mRNA relative to total tissue lysate mRNA (input) LIVER	  Gene	   Expression	   Fold-­‐change	  ±	  SEM	   p-­‐value	  
Alb Hepatic 0.15	  ±	  0.041	   < 5.74 x 10-3	  
F2 Hepatic 0.20	  ±	  0.046	   < 6.00 x 10-3	  
F5 Hepatic 0.19	  ±	  0.060	   < 1.24 x 10-2	  
F7 Hepatic 0.15	  ±	  0.042	   < 4.50 x 10-3	  
F10 Hepatic 0.19	  ±	  0.049	   < 6.75 x 10-3	  
  	   	  
Cdh5 Endothelial 21.69	  ±	  6.02	   < 2.90 x 10-3	  
Tek Endothelial 20.46	  ±	  4.12	   < 8.70 x 10-4	  
Vcam1 Endothelial 21.14	  ±	  2.22	   < 1.30 x 10-4	  
Vwf Endothelial 17.73	  ±	  5.27	   < 2.89 x 10-3	  	   	   	   	  
F8 ? 16.49	  ±	  2.09	   < 2.22 x 10-4	  KIDNEY	  Gene	   Expression	   Fold-­‐change	  ±	  SEM	   p-­‐value	  
Aqp2 Kidney 0.066	  ±	  0.023	   < 4.10 x 10-3	  
Cdh16 Kidney 0.15	  ±	  0.074	   < 1.79 x 10-2	  
Umod Kidney 0.068	  ±	  0.023	   < 1.76 x 10-2	  
  	   	  
Cdh5 Endothelial 20.93	  ±	  4.40	   < 7.00 x 10-4	  
Tek Endothelial 22.54	  ±	  7.03	   < 3.06 x 10-3	  
Vcam1 Endothelial 11.07	  ±	  2.78	   < 4.79 x 10-3	  
Vwf Endothelial 9.93	  ±	  2.74	   < 1.77 x 10-2	  	   	   	   	  
F8 ? 7.40	  ±	  1.11	   < 1.60 x 10-3	  BRAIN	  Gene	   Expression	   Fold-­‐change	  ±	  SEM	   p-­‐value	  
Penk Brain 0.043	  ±	  0.0034	   < 3.38 x 10-5	  
Tac Brain 0.035	  ±	  0.0051	   < 3.12 x 10-4	  
  	   	  
Cdh5 Endothelial 11.77	  ±	  1.38	   < 2.50 x 10-4	  
Tek Endothelial 19.39	  ±	  1.87	   < 7.25 x 10-5	  
Vcam1 Endothelial 4.66	  ±	  1.04	   < 7.95 x 10-3	  
Vwf Endothelial 18.41	  ±	  2.02	   < 1.10 x 10-4	  	   	   	   	  
F8 ? 0.25	  ±	  0.085	   > 1.10 x 10-1	  HEART	  Gene	   Expression	   Fold-­‐change	  ±	  SEM	   p-­‐value	  
Fabp3 Heart 0.28	  ±	  0.012	   < 1.66 x 10-3	  
Myh6 Heart 0.11	  ±	  0.056	   < 1.20 x 10-2	  
Tnnt2 Heart 0.065	  ±	  0.017	   < 1.22 x 10-3	  
  	   	  
Cdh5 Endothelial 4.56	  ±	  0.76	   < 3.20 x 10-3	  
Tek Endothelial 4.43	  ±	  0.92	   < 4.60 x 10-3	  
Vcam1 Endothelial 4.79	  ±	  1.23	   < 6.60 x 10-3	  
Vwf Endothelial 4.40	  ±	  1.08	   < 7.30 x 10-3	  	   	   	   	  
F8 ? 0.67	  ±	  0.22	   > 1.75 x 10-1	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Figure 2-1:  Lman1 mutant alleles 
(A) The Lman1 conditional gene-trap allele (Lman1cgt) contains a gene-trap insertion in 
intron 1 flanked by 2 FRT sites.  Mice carrying this allele were crossed to β-actin FLP 
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transgenic mice.  Mice heterozygous for the resulting Lman1 floxed allele (Lman1fl) were 
crossed to Alb-Cre+ or Tek-Cre+ transgenic mice to excise exons 2 and 3, generating the 
Lman1 null allele (Lman1-) in selected tissues.  Gray blocks represent exons.  A, B, C, D, 
and E represent genotyping primers.  (Adapted from the Knockout Mouse Project.  
General conditional gene targeting scheme: 
https://www.komp.org/alleles.php#conditional-promoter; Lman1 targeting: 
https://www.komp.org/geneinfo.php?geneid=66654); cgt, conditional gene trap; fl, 
floxed; En2 SA, splice acceptor of mouse En2 exon 2; IRES, encephalomyocarditis virus 
(EMCV) internal ribosomal entry site; lacZ, E.coli β-galactosidase gene; pA, SV40 
polyadenylation signal; βact:neo, human β-actin promoter-driven neomycin cassette.  (B) 
A three-primer PCR assay (primers C, D, and E) distinguishes the Lman1+ allele (434 bp) 
from Lman1cgt (565 bp).  (C) PCR genotyping assay used for tail-snip genomic DNA 
from a Lman1fl/fl, Alb-Cre+ mouse, with the addition of a liver biopsy genomic DNA 
sample from the Lman1fl/fl, Alb-Cre+ mouse to demonstrate excision of Lman1 exons 2 
and 3 in the liver.  A three-primer PCR assay (primers A, B, and C) distinguishes the 
Lman1+ (444 bp), Lman1cgt (508 bp), Lman1fl (508 bp), and Lman1- (635 bp) alleles.  
Alb-Cre primers were used to determine the Cre genotype of offspring from matings of 
Lman1fl/+, Alb-Cre+ mice with Lman1fl/fl mice.  Comparison of the signal in DNA from 
liver tissue of an Lman1fl/fl, Alb-Cre+ mouse (lane 7) to tail DNA from the same animal 
(lane 6), indicates a high degree of specific excision in the liver.  A similar PCR 
genotyping strategy of tail-snip genomic DNA was used to identify Lman1fl/fl, Tek-Cre+ 
mice, with primer trio A/B/C demonstrating the Lman1 genotype and with Tek-Cre 
specific primers rather than Alb-Cre primers (not shown).  (D) Western blot of spleen, 
heart, liver, pancreas, lung, and kidney tissues from a wild-type C57BL/6J mouse and a 
Lman1fl/fl, Alb-Cre+ (hepatocyte-knockout) mouse, demonstrating nearly-complete and 
tissue-specific Lman1 knockout in the liver of Lman1fl/fl, Alb-Cre+ mice.  The lower 
molecular weight band observed in the heart samples represents a non-specific band due 
to cross-reactivity with the LMAN1 antibody, since this same band is observed in the 
heart tissue of ubiquitous Lman1-/- null mice (not shown). 
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Figure 2-2:  FV and FVIII activity levels for Lman1 conditional knockout mice. 
Lman1fl/+ and Lman1fl/fl mice were pooled as controls.  Data for Lman1gt1/gt1 mice95 
(previously reported) is included for comparison.  (A) Plasma FV activity measured by 
PT-based coagulation assay.  Lman1fl/fl, Alb-Cre+ mice exhibit a statistically significant 
reduction in plasma FV activity, relative to control mice (p < 1.5 x 10-10), and are 
indistinguishable from Lman1gt1/gt1 mice (p > 0.5).  In contrast, FV activity levels for 
Lman1fl/fl, Tek-Cre+ mice are not reduced.  (B) Plasma FVIII activity measured by PTT-
based coagulation assay.  Lman1fl/fl, Tek-Cre+ mice exhibit a statistically significant 
reduction in plasma FVIII activity, relative to control mice (p < 1.7 x 10-8), and are 
indistinguishable from Lman1gt1/gt1 mice (p > 0.3).  FVIII activity levels for Lman1fl/fl, 
Alb-Cre+ mice are not reduced.  Each symbol represents an individual animal.  
Horizontal lines indicate mean and error bars indicate standard error of the mean for each 
genotype.   
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Figure 2-3:  Relative FV antigen in plasma and platelets of Lman1 conditional 
knockout mice. 
(A) Platelet-poor plasma (equal volume) and (B) isolated platelets (equal number) from 
conditional Lman1 knockout mice and littermate control mice were analyzed for relative 
FV antigen levels by Western blot.  The same plasma samples were run twice as 
duplicates.  Plasma IgG serves as a loading control for the plasma samples, and β-actin 
serves as a loading control for platelets.  Three adult mice were analyzed per genotype.  
Plasma from F5-/- mice carrying a platelet-specific F5 transgene49 was included as a 
negative control for the plasma samples.  Similarly, platelets isolated from a F5-/- mouse 
carrying a hepatocyte-specific F5 transgene49 were included as a negative control for the 
platelet samples. 
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Figure 2-4:  F8 mRNA is expressed in selective endothelial cell beds. 
Plots show fold-change (enrichment or depletion) of mRNA transcripts for a number of 
genes in the endothelial cell mRNA isolated from (A) liver, (B) kidney, (C) brain, and 
(D) heart tissues of four RiboTag, Tek-Cre+ mice, relative to the whole tissue lysate input 
(set to 1.0).  Values less than 1.0 indicate depletion in the endothelial cell fraction, 
relative to input.  In contrast, values greater than 1.0 indicate enrichment.  Each symbol 
represents an independent animal.  Values for tissue-specific, non-endothelial cell genes 
are shown as open circles.  Values for endothelial cell-specific genes are shown as light 
grey squares.  Values for F8 mRNA fold-change are shown as black diamonds.  
Horizontal lines indicate mean and error bars indicate standard error of the mean for each 
genotype. 
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Supplementary Figure 2-1:  Confirmation of Lman1cgt KOMP allele genomic 
targeting by long-range PCR 
Long-range PCR was used to confirm correct genomic targeting of the Lman1cgt allele in 
ES cell clone B06 on the 5’ and 3’ ends of the targeting construct.  (A) Two independent 
forward primers were used to confirm the 5’ targeting of the KOMP allele (LR-A-Fwd 
and LR-B-Fwd) in combination with a common reverse primer (LR-A/B-Rev).  The 
expected PCR amplicon sizes for these two primer pairs are 5,103 bp and 6,405 bp, 
respectively.  To confirm targeting on the 3’ end of the construct, a forward primer in the 
gene-trap cassette (LR-C-Fwd) and a reverse primer downstream of the Lman1 gene (LR-
C-Rev) were used, and the resulting PCR amplicon is expected to be 9,171 bp.  (B) All 
three long-range primer pairs (A, B, and C) generated a single specific band of the 
expected nucleotide length when amplified with genomic DNA from the ES B06 clone.  
As expected, no PCR product was generated when negative control wild-type C57BL/6J 
genomic DNA was used as the PCR template.  
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CHAPTER 3 : 
CHARACTERIZATION OF LMAN1-DEFICIENT MICE  
 
Note:  Chapter 3 is in preparation for submission to Blood as a regular article in March, 
2014 (Authors: Lesley Everett, Rami Khoriaty, and David Ginsburg).  Lesley Everett 
performed all experiments and prepared samples for imaging and histologic analyses.  
Rami Khoriaty assisted with collection and analysis of blood and bone marrow samples.  
Pathology analysis was performed by the University of Michigan Pathology Department 
and the ULAM Pathology Cores for Animal Research. 
 
 
INTRODUCTION 
 
LMAN1 is a type-1 transmembrane receptor protein that cycles between the Endoplasmic 
Reticulum (ER) and the Endoplasmic Reticulum Golgi Intermediate Compartment 
(ERGIC) in the early secretory pathway.  LMAN1 (also known as ERGIC-53) has an ER 
luminal carbohydrate recognition domain for the binding of high mannose glycans,140,141 
and it has a 12 amino-acid cytosolic domain for interactions with the COPII coat.  
LMAN1 binds in a 1:1 ratio with the soluble, 16 kDa protein MCFD2, which localizes to 
the ER and ERGIC due to its interactions with LMAN1.  Together, these proteins form 
the only known mammalian cargo receptor complex in the early secretory pathway.   
 
The LMAN1/MCFD2 receptor is required for efficient secretion of coagulation factor V 
(FV) and factor VIII (FVIII) to the plasma.  Mutations in either LMAN1 or MCFD2 cause 
combined deficiency of coagulation factors V and VIII (F5F8D), an autosomal recessive 
bleeding disorder characterized by reduction of both FV and FVIII to ~10-15% of normal 
levels.3,4  LMAN1 and MCFD2 are ubiquitously expressed and highly evolutionarily 
conserved.  LMAN1 orthologs are present in multiple vertebrate and invertebrate species 
(including C. elegans and D. melanogaster), prior to the evolutionary establishment of a 
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coagulation system, suggesting that the LMAN1/MCFD2 cargo receptor plays a broader 
role in protein secretion.  It is therefore surprising that only a small number of LMAN1-
dependent secretory cargos are currently known.  Other previously reported, but poorly 
characterized, LMAN1 secretory cargos include alpha-1 antitrypsin (A1AT),85 cathepsin 
C (CTSC),87 cathepsin Z (CTSZ),88 and Mac-2 binding protein (M2BP).89 
 
LMAN1 belongs to a family of homologous leguminous type (L-type) mannose-binding 
lectins that function in the trafficking of certain N-linked glycoproteins in the mammalian 
secretory pathway.19-21  Other members of this lectin family include VIP36,22 VIPL,23,24 
and ERGL.25  The L-type lectins share similar carbohydrate recognition domains, but 
they have different subcellular localization patterns and distinct glycoprotein-binding 
specificities.26  LMAN1 is transported from the ER to the ERGIC via COPII coated 
vesicles, and it is recycled back to the ER via COPI vesicles.  The identification of 
LMAN1 as the disease-causing gene in F5F8D provided the first direct evidence that 
LMAN1 acts as a mammalian ER-to-Golgi cargo receptor for FV and FVIII.4  ER cargo 
receptors are transmembrane proteins that specifically recruit secretory proteins into 
budding COPII vesicles at the ER membrane.  They contain ER exit signals that are 
recognized by the SEC24 component of COPII coats.65,142  Only a small number of ER 
cargo receptors have been characterized in detail, most in yeast, and presumably many 
more mammalian ER cargo receptors with critical roles in selective, receptor-mediated 
protein secretion remain to be discovered.67  
 
Analyses in human F5F8D patients with defects in LMAN1 reveal that most patients carry 
two null LMAN1 mutations predicted to result in complete absence of the LMAN1 
protein, as opposed to missense mutations that could potentially confer a less damaging 
effect on protein function.  This suggests that even low levels of residual LMAN1 
function are sufficient to support normal FV and FVIII secretion levels. 
 
We previously described Lman1 mutant mice carrying a gene-trap insertion in intron 10  
(Lman1gt1).95  Lman1gt1/gt1 mice have ~50% of normal FV and FVIII activity level, 
relative to wild-type controls, and are therefore less severely affected than human F5F8D 
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patients.  These mice also exhibit retention of A1AT in the hepatocyte ER, but normal 
steady state plasma A1AT levels and no significant induction of ER stress or unfolded 
protein response (UPR) genes.95  The less severe reductions of FV and FVIII in 
Lman1gt1/gt1 mice relative to that of F5F8D patients could be explained by low levels of 
residual LMAN1 from the gene-trap allele, or differences in FV and FVIII secretion 
between mice and humans.  Lman1gt1/gt1 mice also exhibit a partially penetrant, perinatal 
lethality that is restricted to certain genetic strain backgrounds.95   
 
We now report analysis of a second, independent LMAN1-deficient mouse with no 
Lman1 gene expression (Lman1-/-), as well as hypomorphic LMAN1-deficient mice that 
retain ~7% of normal Lman1 gene expression levels.  The null Lman1-/- mice exhibit FV 
and FVIII plasma activity levels that are ~50% of wild-type levels (comparable to 
Lman1gt1/gt1 mice).  In contrast, hypomorphic LMAN1-deficient mice (Lman1cgt/cgt) that 
retain a low level of wild-type LMAN1 expression exhibit intermediate reductions in FV 
and FVIII.  We confirm the previously reported strain-specific, perinatal lethality of 
LMAN1-deficient mice, and we describe the previously unreported phenotype of 
moderate thrombocytopenia in Lman1-/- mice.  
 
 
MATERIALS AND METHODS 
 
Lman1 and Mcfd2 mutant mice 
Lman1gt1 mice were described previously95 and are maintained on a C57BL/6J genetic 
background.  The Lman1gt1 allele carries a gene-trap insertion in Lman1 intron 10 (Figure 
3-1A).  PCR genotyping for the Lman1gt1 allele was performed as previously described.95  
 
Lman1cgt (Figure 3-1B) and Lman1fl (see Chapter 2) mice were previously described 
(Everett et al., manuscript in press; Chapter 2) and are maintained on a C57BL/6J genetic 
background.  PCR genotyping for the Lman1cgt and the Lman1fl alleles was performed as 
previously described (Everett et al., manuscript in press; Chapter 2).  The Lman1fl allele 
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may be converted to the null Lman1- allele (Lman1tm1d(KOMP)Wtsi) (Figure 3-1C) by Cre-
mediated excision of exons 2 and 3.  Transgenic C57BL/6J mice carrying Cre 
recombinase driven by a ubiquitous EIIA promoter (B6.FVB-Tg(EIIa-cre)C5379Lmgd/J; 
stock no. 003724) were obtained from The Jackson Laboratory.  Lman1fl/+ mice were 
mated to EIIA-Cre+ transgenic mice to generate Lman1+/- mice, which were subsequently 
backcrossed to C57BL/6J mice to achieve germline transmission of the Lman1- allele.  
The resulting Lman1+/- mice were intercrossed to generate Lman1-/-  null mice.  
129S1/SvImJ mice (stock no. 002448) were obtained from The Jackson Laboratory.  
Lman1+/-  (C57BL/6J, 129S1/SvImJ) F1 mice (mixed genetic background designated 
B6;129) were generated and subsequently intercrossed to generate F2 mice.  Primer trio 
A/B/C was used to distinguish between the Lman1+, Lman1fl, and Lman1- alleles (Figure 
3-2). 
 
An MCFD2 null mouse was previously generated by deleting exons 2 and 3 of the Mcfd2 
gene (Zhang et al., manuscript in preparation).  Mcfd2-/- mice exhibit FV and FVIII levels 
that are ~45-50% of wild-type levels, but unlike LMAN1-deficient mice, lethality of 
Mcfd2-/- mice was not observed.  The Mcfd2- allele was maintained on a C57BL/6J 
genetic background and PCR genotyping was performed as previously described (Zhang 
et al., manuscript in preparation).   
 
Genotyping for all animals reported in this study was performed with mouse tail clip 
DNA using Go-Taq Green Master Mix (Promega) and the relevant primers listed in Table 
3-1.  The resulting PCR products were resolved by 2% agarose gel electrophoresis.  For 
tissue collection, mice were anesthetized and cardiac perfusion with 10 mL of PBS was 
performed, after which tissues were isolated and snap frozen in liquid nitrogen for protein 
and RNA isolation.  Timed matings were performed by intercrossing Lman1+/- mice.  The 
following morning, designated embryonic day 0.5 (E0.5), matings were separated.  
Pregnant female mice were euthanized at E18.5 post-coitus.  A tail biopsy was first 
obtained from each fetus for genotyping.  Recovered fetuses were separated and placed 
individually in Z-fix (Aqueous Buffered Zinc Formalin, Anatech LTD) fixative solution 
in preparation for histologic examination. All animals were housed according to the 
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guidelines of the University of Michigan Unit of Laboratory Animal Medicine.  The 
University of Michigan’s University Committee on the Use and Care of Animals 
approved all animal protocols in this study under protocol number 08571. 
 
mRNA isolation and gene expression analysis 
Total mRNA was isolated from a panel of frozen tissues from adult wild-type mice, 
Lman1gt1/gt1 mice, and Lman1cgt/cgt mice using the QIAshredder (Qiagen) and RNeasy 
Kits (Qiagen), as per manufacturer’s instructions, including the optional DNaseI 
digestion step on column.  For the RT-PCR experiment, cDNA synthesis and PCR were 
carried out in one reaction using the Superscript III One-step RT-PCR System with 
Platinum Taq (Invitrogen) and primers listed in Table 3-1.  For the qRT-PCR analyses, 
total mRNA (1 ug) isolated from tissues was converted to cDNA with the Superscript 
First-Strand system (Invitrogen) using oligoDT primers.  qPCR was executed with 
SYBR-Green RT-PCR Master Mix (Applied Biosystems) and primers listed in Table 3-1 
on a 7900HT Fast Real-Time PCR machine (Applied Biosystems).  Data were analyzed 
using the comparative threshold cycle method,112 with the ΔCt value for Lman1 related to 
the ΔCt value of Gapdh, a housekeeping gene used as an internal control.  
 
The cDNA primers utilized for these assays were chosen based on the differences in the 
Lman1cgt and Lman1gt1 alleles (Figure 3-3A).  The Lman1cgt allele has a gene-trap in 
Lman1 intron 1, while the Lman1gt1 allele has a gene-trap in intron 10.  Primer pairs F4-
R2 and F6-R6 span intron 1 and should detect splicing around the Lman1cgt gene-trap, 
while primer pair F5-R5 spans intron 11 and should detect transcriptional activity 
downstream of the Lman1gt1 gene-trap in intron 10 (in the case of splicing around the 
Lman1gt1 gene-trap).  Primer pair F5-R5 was used, in part, because it is comparable to an 
RT-PCR primer pair used in the initial report of Lman1gt1/gt1 mice.95   
 
Tissue histology 
An autopsy and histological survey was performed on adult Lman1-/- mice.  Tissues were 
collected from anesthetized and perfused adult mice and placed directly in Z-Fix for 
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fixation prior to submission to the University of Michigan Cancer Center Histology Core 
for sectioning and H&E staining.  Histologic analysis of adult tissues was performed by 
the University of Michigan Department of Pathology.  Embryos harvested at E18.5 as 
well as five litters of newborn pups from Lman1+/- x Lman1+/- intercrosses were 
sacrificed within ~ 6 hours of birth for fixation (Z-Fix) and necropsy analysis, blinded to 
genotype, was provided by the veterinary pathologists of the University of Michigan 
Pathology Cores for Animal Research facility.  
 
Blood and bone marrow analyses 
Mice were anesthetized briefly with isoflurane and seventy microliters of blood were 
drawn from the retro-orbital venous sinus.  Blood was diluted 70:130 in 5% Bovine 
Serum Albumin (BSA) in Phosphate Buffered Saline (PBS, pH 7.4).  A complete blood 
count (CBC) was performed on the Advia120 Whole Blood Analyzer (Bayer) according 
to the manufacturer’s instructions.  Blood smears were performed as previously 
described143 and were evaluated by a hematologist (RK) blinded to the mouse genotype.  
 
Following pentobarbital-induced anesthesia, bone marrow (BM) was flushed from femurs 
and tibias using RPMI 1640 (Sigma-Aldrich) supplemented with 5% FBS.  BM cells 
were collected by centrifugation in a Rotofix 32A cytospin (Hettich), stained with the 
HEMA 3 kit (Fisher), and examined under light microscopy.  BM cytospins were 
evaluated by an investigator blinded to mouse genotype.  
 
Femurs from Lman1-/- and wild-type control adult mice were harvested to assess bone 
marrow cellularity and architecture.  The samples were processed, embedded, sectioned, 
and stained at the University of Michigan Pathology Cores for Animal Research facility.  
The femurs were fixed in 10% neutral buffered formalin prior to processing, and the 
bones were decalcified in Immunocal (Decal Chemical Corporation) for 24 hours.   
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Platelet isolation and transmission electron microscopy  
Platelet-rich plasma and platelet pellets were isolated and processed as follows: 2 mL of 
room temperature Buffered Saline Glucose Citrate (BSGC) (129 mM NaCl, 13.6 mM Na3 
citrate, 11.1 mM glucose, 1.6 mM KH2PO4, 8.6 mM NaH2PO4, pH 7.3) were placed in a 
5 mL polypropylene tube, to which was added 1-1.5 mL of whole blood.  BSGC was 
added to a final volume of 4 mL, and gently mixed by inversion.  The tubes were 
centrifuged at 180 x g for 10 minutes at room temperature without brake.  The 
supernatant (semi-platelet rich plasma) was removed and centrifuged in fresh tubes at 700 
x g for 10 minutes with brake.  The resulting isolated platelet pellets were resuspended 
and fixed in 2.5% glutaraldehyde in 0.1 M Sorensen’s buffer (0.1 M Na2HPO4, 0.1 M 
KH2PO4, pH 7.4) overnight at 4°C.  Sample processing and transmission electron 
microscopy (TEM) was performed at the University of Michigan Microscopy & Image 
Analysis Laboratory.  Platelets were rinsed in 0.1 M Sorensen’s buffer and fixed with 1% 
osmium tetroxide in 0.1 M Sorensen’s buffer, then rinsed in double distilled water, and 
subsequently stained en bloc with aqueous 3% uranyl acetate for 1 hour.  Platelets were 
dehydrated in ascending concentrations of ethanol, rinsed twice in 100% ethanol, and 
embedded in epoxy resin. Samples were ultra-thin sectioned at 70 nm thickness and 
stained with uranyl acetate and lead citrate. TEM was performed using a Philips CM100 
electron microscope at 60kV.  Images were recorded digitally using a Hamamatsu 
ORCA-HR digital camera system operated with AMT software (Advanced Microscopy 
Techniques Corp., Danvers, MA).  
 
Measurement of FV and FVIII levels 
Blood collection via inferior vena cava (IVC) puncture and platelet-poor plasma isolation 
were performed as previously described (Everett et al., manuscript in press; Chapter 2).  
Plasma FV and FVIII activity levels were determined in prothrombin time- (PT) and 
partial thromboplastin time- (PTT) based assays, respectively, as previously described 
(Everett et al., manuscript in press; Chapter 2).   
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Western blots 
Western blot analysis of mouse tissues and plasma samples was performed according to 
standard protocols.  Briefly, frozen tissues were homogenized in ice-cold lysis buffer 
(100 mM Tris, pH 7.5, 1% NP-40, 10% glycerol, 25 mM β-glycerol phosphate, 130 mM 
NaCl, 10 mM NaF, 5 mM MgCl2, 1 mM EDTA) supplemented with complete protease 
inhibitor (Roche).  Cell lysates were cleared by centrifuging for 10 minutes at 13.2 x 103 
rpm in an Eppendorf 5415D microcentrifuge.  After normalizing protein concentrations 
by DC protein assay (Bio-Rad), 30 ug of protein from each tissue was fractionated by 
SDS-PAGE and transferred to nitrocellulose (Bio-Rad).  Equal volumes of mouse plasma 
from individual animals were used for Western blot analysis of plasma proteins.  
Antibodies used in Western blot experiments were: a monoclonal antibody against 
GAPDH (EMD Millipore), a monoclonal antibody against RALA (Sigma-Aldrich), a 
polyclonal antibody against Alpha-1 antitrypsin (Genway Biotech), and a polyclonal 
antibody against LMAN1 (Sigma-Aldrich).  HRP was detected using an enhanced 
chemiluminescence kit (Perkin-Elmer).  ER accumulation of A1AT in liver tissues was 
evaluated by using an IRDye-conjugated secondary antibody (LI-COR Biosciences) and 
quantifying the band intensities using the Odyssey Infrared Imaging System.  The 
Odyssey CLx Image Studio program (LI-COR Biosciences) was used for analysis. 
 
Statistical analysis 
A chi-squared test was used to evaluate statistical deviation from expected Mendelian 
ratios for the genotypes of offspring from the matings listed in Table 3-2.  Analysis of the 
FV and FVIII activity assays was performed by one-way ANOVA for comparisons of 
more than two groups, or by student’s t-test for comparison of two groups.  Statistical 
analysis of CBC data for Lman1 mutant mice compared to wild-type mice was performed 
using a student’s t-test with a Bonferroni correction for multiple observations, with a p-
value < 0.00625 considered statistically significant (8 CBC parameters evaluated).  One-
way ANOVA was also performed for an overall comparison of the mean platelet count 
for each genotype.  A p-value ≤ 0.05 was considered to be statistically significant for all 
other analyses.  Statistical analysis of the ratios of post-ER A1AT:ER-retained A1AT for 
Lman1 mutant mice and wild-type control mice was performed using a student’s t-test to 
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compare two specific genotypes, as well as with one-way ANOVA to compare the means 
of all genotypes.   
 
 
RESULTS 
 
LMAN1 deficiency results in perinatal lethality with incomplete penetrance 
The genotype distribution of offspring from intercrosses of Lman1gt1/+ mice on a 
C57BL/6J genetic background revealed a small but significant reduction in the number of 
observed homozygote Lman1gt1/gt1 mice at 3 weeks of age compared to Mendelian 
prediction (17% observed vs. 25% expected, p < 0.003) (Table 3-2), consistent with the 
previous report (9-15% of pups were Lman1gt1/gt1 on three genetic strain backgrounds).95   
 
Heterozygous Lman1fl/+ mice were crossed with transgenic EIIA-Cre+ mice that carry the 
Cre recombinase gene driven by the ubiquitously expressed adenovirus EIIA promoter to 
generate Lman1+/- mice, which were maintained on a C57BL/6J genetic background.  
The resulting Lman1+/- mice were intercrossed to generate Lman1-/- mice.  Similar to 
Lman1gt1/gt1 mice, perinatal lethality with incomplete penetrance was observed for 
Lman1-/- mice (p < 0.007) (Table 3-2), thereby ruling out a passenger gene effect as the 
cause of the originally reported lethality.  Genotyping of pups from this intercross that 
died spontaneously at P0 revealed an excess of Lman1-/- mice (11/22 pups) (p < 0.007).  
In contrast, Lman1cgt/cgt mice on a C57BL/6J genetic background are viable and were 
observed in the expected Mendelian ratios (p > 0.19) (Table 3-2).  
 
To assess Lman1-/- lethality on a mixed genetic background, the Lman1- allele was 
outcrossed to the 129 SvImJ genetic background.  Offspring from intercrosses of 
Lman1+/- (B6;129) F1 mice were observed in the expected Mendelian ratios, with no 
evidence for perinatal lethality among Lman1-/- mice on this genetic background (p > 
0.79) (Table 3-2).  These results are consistent with the original Lman1gt1/gt1 report.95 
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No consistent abnormalities were observed on routine autopsy and histologic examination 
of adult Lman1-/- mice (Supplementary Figure 3-1) or on necropsy of Lman1-/- pups and 
wild-type littermates sacrificed at embryonic day 18.5 (E18.5) or several hours after 
birth.   
 
Comparison of Lman1 expression from different mutant alleles 
LMAN1 protein levels in liver lysates prepared from Lman1gt1/gt1 mice, Lman1cgt/cgt mice, 
and Lman1-/- mice were compared by Western blot analysis (Figure 3-4A), demonstrating 
that LMAN1 is expressed with variable levels in the different Lman1 mutant mouse 
strains.  Relative to wild-type mice, the Lman1cgt/+ (lane 2), Lman1+/- (lane 4), and 
Lman1gt1/+ (lane 6) heterozygote animals express moderately reduced levels of LMAN1.  
The Lman1cgt/cgt mice (lane 3) retain a low level of residual LMAN1 expression, 
indicating that the Lman1cgt allele is not a null allele.  In contrast, LMAN1 protein is not 
detectable by Western blot in either the Lman1-/- (lane 5) or Lman1gt1/gt1 (lane 7) samples.  
Analysis of several Lman1cgt/cgt mouse tissues reveals detectable LMAN1 expression at 
varying levels (Figure 3-4B).   
 
RT-PCR and qPCR on liver samples were performed to assess Lman1 mRNA expression.  
Lman1cgt/cgt mice exhibit detectable wild-type Lman1 mRNA by RT-PCR, consistent with 
the Western blot results (Figure 3-3B).  An alternate splice product of the Lman1cgt allele 
was also observed (Figure 3-5).  In contrast, RT-PCR analysis detected no wild-type 
Lman1 mRNA in Lman1gt1/gt1 mice (Figure 3-3B).  
 
qPCR analysis demonstrated that Lman1cgt/cgt mice retain ~5-7% of normal levels of 
Lman1 mRNA expression in the liver and kidney (Figure 3-3 C-F).  qPCR of liver 
mRNA from Lman1gt1/gt1 mice detected no wild-type mRNA (Figure 3-3D), though with 
evidence for reduced stability of the β-geo fusion mRNA compared to wild-type Lman1 
mRNA (Figure 3-3C).  
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Lman1-/- mice are thrombocytopenic 
Relative to wild-type mice, Lman1-/- mice exhibit normal CBC parameters (Figure 3-6 A-
G), with the exception of a mild, isolated thrombocytopenia (p < 0.004 with Bonferroni 
correction) (Figure 3-6H).  In contrast, Lman1+/- mice, Lman1cgt/cgt mice, and Mcfd2-/- 
mice all exhibit normal platelet counts indistinguishable from C57BL/6J wild-type 
control mice (Figure 3-7).  No platelet abnormalities were detected in peripheral blood 
smears of Lman1-/- mice (Figure 3-8A).  Longitudinal histologic sections of mouse 
femurs also revealed no abnormalities in bone marrow cellularity or architecture (Figure 
3-8B; Supplementary Table 3-1).  TEM of platelets isolated from Lman1-/- mice and 
wild-type littermate controls revealed no differences in platelet morphology, as assessed 
by three independent reviewers blinded to mouse genotype (Figure 3-9). 
 
Relationship between Lman1 expression and LMAN1-dependent FV and FVIII 
secretion 
Lman1-/- null mice on a pure C57BL/6J genetic background or on a mixed B6;129 genetic 
background exhibit plasma FV (Figure 3-10A, Figure 3-10C) and FVIII (Figure 3-10B, 
Figure 3-10D) activity levels that are ~50% of wild-type levels, consistent with the 
previous report for Lman1gt1/gt1 mice.95  In contrast, Lman1cgt/cgt mice exhibit plasma FV 
(Figure 3-10A) and FVIII (Figure 3-10B) activity levels that are moderately reduced to 
~67% (p < 3.0 x 10-4) and ~63% (p < 9.2 x 10-7) of wild-type levels, respectively.  Plasma 
FV (Figure 3-11A) and FVIII (Figure 3-11B) activity levels are indistinguishable 
between Lman1gt1/gt1 mice and Lman1-/- mice.   
 
Consistent with previous reports of Lman1gt1/+ mice95 and with the autosomal recessive 
inheritance of F5F8D, heterozygous carriers of the Lman1cgt, Lman1gt1, and the Lman1- 
mutant alleles on either a pure C57BL/6J genetic background (Figure 3-12A and Figure 
3-12B) or on a mixed B6;129 genetic background (Figure 3-12C and Figure 3-12D) 
demonstrate FV and FVIII activity levels indistinguishable from control mice. 
 
FV and FVIII plasma activity levels of Lman1-/- mice were compared directly to that of 
Mcfd2-/- mice, the other murine model of F5F8D.  There was a trend (p > 0.08) for FV 
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activity levels to be slightly lower in Mcfd2-/- mice as compared to Lman1-/- mice (Figure 
3-13A), which is consistent with previous reports of FV and FVIII plasma levels in 
human F5F8D patients with MCFD2 mutations as compared to LMAN1 mutations.39  
However, FVIII activity was indistinguishable between Lman1-/- and Mcfd2-/- mice 
(Figure 3-13B).   
 
ER accumulation of A1AT in the Lman1 allelic series 
Western blot analysis of Lman1gt1/gt1 hepatic lysates confirmed the previous report of 
A1AT retention in the ER (Figure 3-14A).95  A1AT also accumulates in the ER of 
Lman1cgt/cgt mice and Lman1-/- mice, relative to wild-type control mice (Figure 3-14A).  
Null Lman1-/- mice demonstrate the highest levels of A1AT ER retention, with 
intermediate levels in the Lman1cgt/cgt mice (Figure 3-14B). 
 
 
DISCUSSION  
 
We report the characterization of a series of Lman1 mutant alleles (summarized in Table 
3-3), with Lman1 gene expression ranging from ~7% of normal levels (Lman1cgt/cgt mice) 
to no gene expression (Lman1-/-).  We exclude trace residual LMAN1 expression as the 
explanation for the more modest reduction in FV and FVIII in previously reported gene 
targeted mice95 compared to humans with F5F8D, and observe an intermediate level of 
FV and FVIII reduction in Lman1cgt/cgt mice.  We confirmed the previously reported 
partially penetrant, perinatal, strain-specific lethality of LMAN1-deficient mice.95  In 
addition, we report that Lman1-/- mice are mildly thrombocytopenic, with no detectable 
histologic defect in the bone marrow or peripheral blood.   
 
In the original report of the Lman1gt1/gt1 F5F8D mice, partial perinatal lethality was 
observed on the C57BL/6J, 129/SvImJ, and DBA/2J genetic backgrounds, with no 
significant lethality observed on a mixed B6;129 or A/J genetic background.95  We 
confirm this strain-specific partial lethality in an independent Lman1 targeted allele, 
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excluding a passenger gene effect not due to LMAN1 deficiency as the cause of lethality 
in LMAN1 null mice. 
 
In contrast to the partial lethality observed in Lman1-/- mice, mice homozygous for the 
hypomorphic Lman1cgt allele are observed in expected Mendelian proportions.  Taken 
together with the lack of a similar perinatal phenotype in human F5F8D patients, despite 
much greater reductions in FV and FVIII levels in humans, these data suggest the 
existence of another as yet unknown LMAN1-dependent cargo with a critical function in 
the neonatal period.  Possible explanations for this difference in phenotype include the 
fact that humans (like the outbred B6;129 mice) are more genetically diverse than highly 
inbred C57BL/6J mice, and this genetic diversity is expected to be protective against the 
effects of a deleterious genetic mutation (relative to the homogeneous C57BL/6J genetic 
background).  The different phenotypes in mice and humans could also result from 
biologic or physiologic differences between these species.  For example, there may exist 
a secretory cargo that is essential in mice but not in humans, or that has a different 
function in mice than in humans.  Alternatively, the same cargo may be present in both 
species, but its impaired secretion in humans may not be as limiting as in mice.  
Examination of Lman1-/- pups at E18.5 and at birth has revealed no obvious anatomic or 
histologic abnormalities to suggest the underlying cause of death in these animals.  One 
possible exploratory approach to identify the cause of death in Lman1-/- neonates would 
be to generate a number of different tissue-specific Lman1 knockout strains utilizing 
various tissue-specific Cre recombinases, which would reveal the tissues in which 
LMAN1 deficiency is sufficient to cause neonatal lethality.  
 
The observation that reported F5F8D human patients with LMAN1 mutations carry two 
null Lman1 alleles suggested that even low levels of residual LMAN1 function are 
sufficient to support normal FV and FVIII secretion.36  Our results in the mouse suggest 
an ascertainment bias, with F5F8D patients with milder LMAN1 mutations escaping 
clinical detection.  Based on these data, LMAN1/MCFD2 genetic analyses could be 
considered in patients with only modest reductions in FV and FVIII levels (in the 30-70% 
range).  Previous GWAS analyses of over 23,000 individuals for genetic loci associated 
 57 
with plasma FVIII levels144 failed to identify any signal at the LMAN1 locus on 
chromosome 18, excluding common genetic variants in LMAN1 as a key determinant of 
FVIII variation in the general population.  However, we cannot rule out the possibility 
that LMAN1 variation may moderately contribute to population variation in FV and FVIII 
levels.  The observation that the low level of Lman1 expression in Lman1cgt/cgt mice is 
associated with intermediate reductions in FV, FVIII, and A1AT secretion suggests that 
targeting of LMAN1 to reduce FV and FVIII as an anticoagulant strategy may only 
require partial LMAN1 reduction.   
 
Though A1AT was identified in vitro as an LMAN1-dependent secretory cargo,85 plasma 
levels of A1AT were indistinguishable between two human F5F8D patient siblings, their 
obligate carrier parents, and 2 normal controls.95  Plasma A1AT levels are also 
indistinguishable between Lman1gt1/gt1 mice and wild-type controls, though retained 
within the ER in Lman1gt1/gt1 hepatocytes.95  We confirm retention of A1AT in 
hepatocytes of Lman1 null mice, with intermediate levels in the ER of Lman1cgt/cgt 
hepatocytes.  Thus, a similar relationship between Lman1 gene expression levels and 
LMAN1-dependent cargo secretion applies to A1AT secretion as was observed for FV 
and FVIII secretion. 
 
Complete LMAN1 deficiency in the mouse results in plasma FV and FVIII levels 
reduced to ~50% of normal, compared to ~10-15% levels in human F5F8D patients, 
suggesting the existence of alternative compensatory or parallel mechanisms for the 
secretion of at least some LMAN1-dependent cargos, including FV and FVIII.  
Differences in these alternate secretion pathways between mice and humans (for 
example, the number of alternate pathways, the specificity of each pathway for certain 
cargos, or the rate of cargo transport in the pathways) may account for the difference in 
FV and FVIII secretion levels between mice and humans.   
 
Finally, the observation of mild thrombocytopenia in Lman1-/- mice was unexpected, 
since no such abnormality has ever been noted in human patients.  No other hematologic 
abnormalities were observed in the mouse or previously in human patients.  A previous 
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GWAS analysis for platelet-associated traits in 66,867 subjects identified 68 genetic loci 
associated with platelet count or platelet volume, though no loci associated with platelet 
count are close to the LMAN1 locus.145  These data suggest that common variants at the 
LMAN1 locus do not contribute significantly to platelet count variation in the general 
population.  Given the mild reduction in platelet count in Lman1-/- mice, a similar subtle 
phenotype in human F5F8D patients could have been missed and would likely require 
analysis of a large cohort of F5F8D patients for detection.  Morphologic analyses of 
platelets and megakaryocytes in Lman1-/- mice revealed no abnormalities, and the 
mechanism for this mild thrombocytopenia remains unknown.  However, reduction in 
secretion of another, as yet unknown LMAN1-dependent cargo seems likely.  In this 
case, the cargo could represent either a component of the platelet itself, or an extrinsic 
factor affecting platelet number that is secreted by another cell type. 
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Table 3-1:  Primer sequences 
Primer 5’ à 3’  Sequence 
Genotyping primers 
Lman1 primer A GGCTTTCTTGACACCTTCAATTTAA 
Lman1 primer B CCAAGTGAAGGGAAGACCATCAAGC 
Lman1 primer C GACCCCTAGTGACGGGTTCTTGTC 
Flpe transgene Fwd GGTCCAACTGCAGCCCAAGCTTCC 
Flpe transgene Rev GTGGATCGATCCTACCCCTTGCG 
EIIA-Cre transgene Fwd CCGCTGGAGATGACGTAGTT 
EIIA-Cre transgene Rev CGCATAACCAGTGAAACAGCATTGC 
RT-PCR and qPCR primers 
β-actin Fwd CTAAGGCCAACCGTGAAAAG 
β-actin Rev GGGGTGTTGAAGGTCTCAAA 
Gapdh Fwd TGTGTCCGTCGTGGATCTGA 
Gapdh Rev ACCACCTTCTTGATGTCATCATACTT 
F4 CCGTTTCGAGTACAAATACAGC 
R2 TTGATTTGTCCATTGTTGCCTA 
F5 ACGTGGTGAAGAGAGATATCGAC 
R5 ACAAAGTGGATCGTGGATAGACA 
F6 GCCCAGGCGGGGAATGCTATTCCAAG 
R6 TCTCGAAGGCTGCTTTTGCTTTGGT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
Table 3-2:  Intercrosses of Lman1 mutant mice 
Crosses Strain 
Genotype distribution at 3 
weeks: percent (number 
observed) 
p-value 
(χ2) 
  +/+ and +/- -/-  
Expected %  75 % 25%  
Lman1
gt1/+
 x Lman1
gt1/+
 C57BL/6J 83% (201) 17% (40) < 0.003 
Lman1
cgt/+
 x Lman1
cgt/+
 C57BL/6J 80% (107) 20% (27) > 0.19 
Lman1
+/-
 x Lman1
+/-
 C57BL/6J 83% (184) 17% (38) < 0.007 
Lman1
+/-
 x Lman1
+/-
 B6;129 mixed 76% (95) 24% (30) > 0.79 
 
The chi-squared test was based upon an expected genotype ratio of 3:1, with Lman1-/- mice 
expected to represent 25% of the offspring from each mating, and all other genotypes 
cumulatively accounting for 75% of offspring. 
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Table 3-3:  Summary of homozygous Lman1 mutant mice on C57BL/6J genetic 
background 
Lman1 allele 
% wild-type Lman1 
expression in homozygote 
mice (qRT-PCR) 
Lethality of 
homozygotes? 
FV and FVIII 
activity levels 
Lman1+ 100% NA 100% 
Lman1cgt ~7% No ~70% 
Lman1- 0% Yes (~40%) ~50% 
Lman1gt1 <1% Yes (~40%) ~50% 
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Supplementary Table 3-1:  Histologic evaluation of mouse bone marrow 
Mouse Genotype Myeloid:Erythroid ratio 
Megakaryocyte number (per 
longitudinal section) 
77022 Lman1-/- 1.85 322 
77021 Lman1-/- 1.77 341 
77115 Lman1-/- 1.70 268 
77312 Lman1+/+ 1.94 322 
77327 Lman1+/+ 1.63 354 
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Figure 3-1:  Schematic of Lman1 mutant alleles 
(A) The original, previously published Lman1 gene-trap allele (Lman1gt1) carries a gene-
trap insertion in intron 10.95  SA, splice acceptor cassette; β-Geo, β-galactosidase-neo 
fusion; pA, poly-adenylation sequence.  (B) The Lman1 conditional gene-trap allele 
(Lman1cgt) contains a gene-trap insertion in intron 1 flanked by 2 FRT sites.  Mice 
carrying this allele were crossed to β-actin FLP transgenic mice.  Mice heterozygous for 
the resulting Lman1 “floxed” allele (Lman1fl/+) were crossed to EIIA-Cre+ transgenic 
mice to excise exons 2 and 3, generating (C) the Lman1 null allele (Lman1-).  Gray 
blocks represent exons.  A, B, and C represent genotyping primers.  (Adapted from the 
Knockout Mouse Project. Lman1 targeting: 
https://www.komp.org/geneinfo.php?geneid=66654);  cgt, conditional gene trap; fl, 
floxed; En2 SA, splice acceptor of mouse En2 exon 2; IRES, encephalomyocarditis virus 
(EMCV) internal ribosomal entry site; lacZ, E.coli β-galactosidase gene; pA, SV40 
polyadenylation signal; βact:neo, human β-actin promoter-driven neomycin cassette.   
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Figure 3-2:  Lman1 PCR genotyping strategy 
Lman1fl/+ mice were crossed to EIIA-Cre+ transgenic mice to generate the Lman1- allele.   
A three-primer PCR assay (primers A, B, and C) distinguishes the Lman1+ (444 bp), 
Lman1fl (508 bp), and Lman1- (635 bp) alleles.   Primer pair A/B also distinguishes 
between the Lman1+ allele and the Lman1cgt allele (508 bp) (not shown). 
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Figure 3-3:  Lman1 expression levels in Lman1cgt/cgt and Lman1gt1/gt1 mice 
(A)  Schematic of Lman1gt1 and Lman1cgt alleles.  Primer pairs used for RT-PCR (blue 
and green) and qPCR (red and green) are indicated by arrows.  Primer pair F4/R2 
amplifies Lman1 mRNA transcript between exons 1-4 (393 bp product), while primer 
pair F5/R5 amplifies Lman1 mRNA transcript sequence between exons 11-12 (115 bp 
product).  (B) RT-PCR analysis of Lman1 expression.  β-actin primers were used as a 
positive control.  Primers F4/R2 were used to amplify sequence targets between Lman1 
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exons 1-4 (flanking the Lman1cgt gene-trap), while primers F5/R5 were used to amplify 
target sequences downstream of the Lman1gt1 gene-trap.  Two bands are detected in the 
Ex.1-4 lane for the Lman1cgt/cgt mouse, indicating that splicing around the Lman1cgt gene-
trap occurs.  As indicated by the black arrows, the lower band is the expected 393 bp 
product (WT) while the upper band (Alt.) represents a 508 bp alternatively spliced 
product (see Figure 3-5).  Similarly, downstream exon 11-12 sequences are also 
amplified in the Lman1cgt/cgt mouse, indicating that full-length, wild-type Lman1 mRNA 
transcripts are present in this sample.  In contrast, an expected Ex. 1-4 band is observed 
in the Lman1gt1/gt1 mouse (since the Lman1gt1 gene-trap insertion occurs downstream), but 
no detectable band is observed in the Ex. 11-12 lane for this mouse, consistent with 
complete or nearly complete absence of wild-type Lman1 mRNA transcripts in 
Lman1gt1/gt1 mice.  (C and D) qPCR of liver cDNA from Lman1cgt/cgt and Lman1gt1/gt1 
mice indicates that Lman1cgt/cgt mice retain ~5-6% of normal Lman1 expression in the 
liver, whereas Lman1gt1/gt1 mice retain < 1% of normal expression.  (E and F) qPCR of 
kidney cDNA from Lman1cgt/cgt mice indicates that Lman1cgt/cgt mice retain ~7% of 
normal Lman1 expression in the kidney.  Three mice per genotype were used for qPCR 
analysis.  Horizontal bars represent means, error bars represent standard error of the 
mean. 
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Figure 3-4:  Western blot of LMAN1 expression in Lman1 mutant mice 
 (A) Western blot of liver lysates from heterozygote and homozygote carriers of the 
Lman1 mutant alleles: Lman1cgt, Lman1-, and Lman1gt1.  Lman1cgt/cgt mice are 
hypomorphic, retaining a low level of normal LMAN1 expression due to splicing around 
the gene-trap cassette.  Lman1-/- and Lman1gt1/gt1 mice demonstrate no detectable LMAN1 
protein by Western blotting.  Each lane corresponds to a single animal.  (B) LMAN1 
protein is detected in multiple tissues of Lman1cgt/cgt mice at proportional, but reduced, 
levels relative to wild-type mice.     
 
 
 
 
 
 
 
Lman1+/+( Lman1cgt/cgt(
live
r&
lun
g&
sk.
mu
scl
e&
kid
ne
y&
LMAN1&
RALA&
live
r&
lun
g&
sk.
mu
scl
e&
kid
ne
y&
LMAN1&
GAPDH&&
gt1
/+(
cg
t/c
gt(
cg
t/+
(
gt1
/gt
1(
+/+
(
+/,
(
(,/,
(
(A)&
(B)&
 68 
 
 
Figure 3-5:  Alternative splicing of the Lman1cgt allele 
A 508bp alternatively spliced transcript was observed in Lman1cgt/cgt mice by RT-PCR 
with primers F4/R2 (Figure 3-3B), generated by a splicing event in which 115 
nucleotides from the mouse En2 exon 2 in the KOMP targeting construct was 
incorporated into the transcript.  The strong splice acceptor sequence of the En2 exonic 
sequence was used to drive this alternative splicing event.  An internal pseudo splice-
donor sequence exists immediately following the 115 bp of sequence incorporated into 
the alternative splicing product, facilitating splicing out of the En2 exon and into Lman1 
exon 2. 
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Figure 3-6:  Lman1-/- mice are thrombocytopenic 
Complete blood count analyses for Lman1-/- mice and wild-type control mice. (A) White 
blood cells (WBC), (B) red blood cells (RBC), (C) hematocrit (HCT), (D) mean 
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corpuscular volume (MCV), (E) neutrophils, (F) lymphocytes, and (G) mean platelet 
volume (MPV) were indistinguishable between wild-type control mice and Lman1-/- 
mice.  (H) Platelet count was statistically significantly reduced in Lman1-/- mice relative 
to wild-type control mice (p < 0.0005).  Given that 8 different CBC parameters were 
compared for the wild-type and Lman1-/- mice, a Bonferroni correction was applied to 
account for multiple observations.  A p-value < 0.00625 was therefore considered 
statistically significant for these analyses, and significance is indicated by a (*) in the 
figure.  Each symbol represents an individual animal.  Horizontal lines indicate mean and 
error bars indicate standard error of the mean for each genotype.    
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Figure 3-7:  Thrombocytopenia is unique to Lman1-/- mice 
Platelet counts for Lman1+/+ mice, Lman1+/- mice, Lman1-/- mice, Lman1cgt/cgt mice, and 
Mcfd2-/- mice.  Comparisons between individual genotypes were performed with a 
student’s t-test.  The thrombocytopenia phenotype is specifically observed in Lman1-/- 
mice (p < 0.0004).  The differences among the mean platelet counts were statistically 
significant as determined by one-way ANOVA (F(4,58) = 6.688, p < 0.0002).  Each 
symbol represents an individual animal.  Horizontal lines indicate mean and error bars 
indicate standard error of the mean for each genotype.  The platelet count data for 
Lman1+/+ and Lman1-/- mice are the same as the data points shown in Figure 3-6H.  
 
 
 
 
 
 
 
 
Lm
an
1⁺
/⁺
Lm
an
1⁺
/(
Lm
an
1(
/(
Lm
an
1)
*+/
)*+
Mf
d2
(/(
0
500
1000
1500
2000
Platelet&Count
Genotype
x&
10
³ &c
el
ls/
ul
p"<"0.0004
n.s.
n.s.
n.s.
 72 
 
 
Figure 3-8:  Peripheral blood smears and bone marrow of Lman1-/- mice 
(A) Peripheral blood smears of Lman1-/- and wild-type mice.  (B) Histology 
photomicrographs of bone marrow from an Lman1-/- mouse and wild-type control mouse 
were obtained to assess the bone marrow architecture and cellularity.  Erythroid and 
myeloid progenitors are observed.  Megakaryocyte (arrowheads) morphology appears 
normal in both images (H&E, 60X). 
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Figure 3-9:  Transmission electron micrographs of platelets from Lman1+/+ mice and 
Lman1-/- mice are indistinguishable 
Platelets were isolated from two adult wild-type control mice (77307 and 77038) and two 
Lman1-/- mice (77335 and 77250).  Samples were viewed at 13,500x and 25,000x direct 
magnification.  Three blinded investigators assessed platelet and granule morphology. 
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Figure 3-10:  Plasma FV and FVIII activity levels for Lman1-/- mice on a C57BL/6J 
genetic background does not differ from mixed B6;129 genetic background  
(A) Plasma FV activity measured by PT-based coagulation assay.  Lman1cgt/cgt mice 
(C57BL/6J) exhibit a moderate reduction in plasma FV activity, relative to wild-type 
control mice (67.1% ± 5.3%).  In contrast, Lman1-/- mice (C57BL/6J) demonstrate FV 
activity levels that are 48.7% ± 4.0% of normal, relative to wild-type, which is consistent 
with previously published reports of Lman1gt1/gt1 mice.95  The mean plasma FV activity 
levels for Lman1+/+, Lman1cgt/cgt, and Lman1-/-  mice are statistically significantly 
different, as determined by one-way ANOVA (F(2,44) = 31.33, p < 0.0001).  (B) Plasma 
FVIII activity measured by PTT-based coagulation assay.  Plasma FVIII activity levels in 
Lman1cgt/cgt mice (C57BL/6J) are moderately reduced, relative to wild-type control mice 
(62.8% ± 4.2%).  In contrast, Lman1-/- mice (C57BL/6J) demonstrate a ~50% reduction 
of FVIII activity levels (49.2% ± 4.6%), relative to wild-type, which is consistent with 
previously published reports of Lman1gt1/gt1 mice.95  The mean plasma FVIII activity 
levels for Lman1+/+, Lman1cgt/cgt, and Lman1-/-  mice are statistically significantly 
+/+
cg
t/c
gt -/-
0
50
100
150
200
FV activity (C57BL/6J) 
Lman1 genotype
%
 F
V 
A
ct
iv
ity p"<"0.0001
+/+
cg
t/c
gt -/-
0
50
100
150
200
FVIII activity (C57BL/6J) 
Lman1 genotype
%
 F
VI
II 
ac
tiv
ity p"<"0.0001
+/+ -/
-
0
50
100
150
FV activity (B6;129 F2)
Lman1 genotype
%
 F
V 
A
ct
iv
ity
p"<"0.0001
+/+ -/
-
0
50
100
150
200
FVIII Activity (B6;129 F2)
Lman1 genotype
%
 F
VI
II 
ac
tiv
ity
p"<"0.0001
(A)$ (B)$
(C)$ (D)$
FV#ac&vity:#C57BL/6J# FVIII#ac&vity:#C57BL/6J#
# & it :#(B6;129)#F2# III#ac& it :#(B6;129)#F2#
 75 
different, as determined by one-way ANOVA (F(2,59) = 42.07, p < 0.0001). (C) Lman1-/- 
F2 mice (B6;129) exhibit an ~50% reduction in plasma FV activity, relative to wild-type 
control mice (45.7% ± 3.3%).  (D) Plasma FVIII activity levels in Lman1-/- F2 mice 
(B6;129) are also reduced to ~50% of normal levels (48.8% ± 4.0%).  The reductions in 
plasma FV and FVIII activity in Lman1-/- mice on a mixed B6;129 genetic background 
are comparable to that observed on a pure C57BL/6J genetic background.  Each symbol 
represents an individual animal.  Horizontal lines indicate mean and error bars indicate 
standard error of the mean for each genotype. 
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Figure 3-11:  Plasma FV and FVIII activity levels are indistinguishable for 
Lman1gt1/gt1 and Lman1-/- mice 
(A) Plasma FV activity and (B) plasma FVIII activity for Lman1gt1/gt1 and Lman1-/- mice 
are indistinguishable.  Each symbol represents an individual animal.  Horizontal lines 
indicate mean and error bars indicate standard error of the mean for each genotype. 
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Figure 3-12:  Plasma FV and FVIII activity levels for Lman1 heterozygous mice on a 
C57BL/6J genetic background and mixed B6;129 genetic background are 
indistinguishable from wild-type controls 
(A) Plasma FV activity and (B) plasma FVIII activity for heterozygous carriers of the 
Lman1cgt allele, the Lman1gt1 allele, and the Lman1- allele on a C57BL/6J genetic 
background.  Consistent with the autosomal recessive inheritance of F5F8D, Lman1 
heterozygous mice are indistinguishable from wild-type control mice. (C) Plasma FV 
activity and (D) plasma FVIII activity for Lman1+/- F2 mice (B6;129), relative to wild-
type littermate controls.  Consistent with the results from Lman1+/- mice on a pure 
C57BL/6J genetic background, Lman1+/- F2 mice (B6;129) have plasma FV and FVIII 
activity levels that are indistinguishable from wild-type control mice.  Each symbol 
represents an individual animal.  Horizontal lines indicate mean and error bars indicate 
standard error of the mean for each genotype. 
 
 
+/+
cg
t/+
gt1
/+ +/-
0
50
100
150
200
FV activity (C57BL/6J) 
Lman1 genotype
%
 F
V 
A
ct
iv
ity
p">"0.24
+/+
cg
t/+
gt1
/+ +/-
0
50
100
150
200
FVIII activity (C57BL/6J) 
Lman1 genotype
%
 F
VI
II 
ac
tiv
ity
p">"0.19
(A)$ (B)$
+/+ +/
-
0
50
100
150
200
FV activity (B6;129 F2)
Lman1 genotype
%
 F
V 
A
ct
iv
ity
p">"0.15
+/+ +/
-
0
50
100
150
200
250
FVIII Activity (B6;129 F2)
Lman1 genotype
%
 F
VI
II 
ac
tiv
ity
p">"0.66
(C)$ (D)$
 78 
 
 
Figure 3-13:  Plasma FV and FVIII activity for Lman1-/- and Mcfd2-/- mice 
(A) Plasma FV activity and (B) plasma FVIII activity are indistinguishable between 
Lman1-/- mice and Mcfd2-/- mice.  Each symbol represents an individual animal.  
Horizontal lines indicate mean and error bars indicate standard error of the mean for each 
genotype. 
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Figure 3-14:  A1AT is retained in the ER of LMAN1 deficient mice 
(A) Liver lysates from Lman1cgt/cgt mice, Lman1gt1/gt1 mice, and Lman1-/- mice were 
compared to liver lysates from Lman1+/+ control mice by Western blot to determine the 
extent of A1AT retention in the ER.  The A1AT antibody detects a protein doublet on 
Western blot analysis.  The lower band of the doublet corresponds to ER-retained A1AT, 
and was previously shown to be endoH sensitive.95  The upper band in the doublet 
corresponds to post-ER A1AT, and is comparable in molecular weight to plasma A1AT.  
Each lane represents an individual mouse.  (B) In order to quantify the retention of A1AT 
in the ER of Lman1 mutant mice, relative to wild-type mice, the ratio of post-ER 
A1AT:ER-retained A1AT (upper band:lower band) was quantified for each sample using 
an IRDye-conjugated secondary antibody and the Odyssey Infrared Imaging System, 
with analysis performed on the Odyssey CLx Image Studio program.  The ratio of post-
ER A1AT:ER-retained A1AT is plotted for each animal.  Ratio values < 1.0 indicate that 
the majority of A1AT in the liver sample is retained in the ER, and ratio values > 1.0 
indicate that the majority of A1AT has undergone ER-to-Golgi transport (post-ER).   The 
ratio of post-ER A1AT:ER-retained A1AT follows a similar relationship to Lman1 gene 
expression levels as previously observed for FV and FVIII secretion in the Lman1 mutant 
mice.  Lman1cgt/cgt mice (~7% of normal Lman1 expression) exhibit a slightly higher ratio 
of post-ER A1AT:ER-retained A1AT, as compared to Lman1-/- mice (zero Lman1 
expression).  The ratios for Lman1gt1/gt1 mice and Lman1-/- mice are indistinguishable.  
This indicates that Lman1cgt/cgt mice secrete more A1AT than do the Lman1gt1/gt1 mice 
and Lman1-/- mice.  The differences among the mean ratios were statistically significant 
as determined by one-way ANOVA (F(3,14) = 23.24, p < 0.0001).  Horizontal lines 
indicate mean and error bars indicate standard error of the mean for each genotype.   
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Supplementary Figure 3-1:  Adult Lman1-/- tissues are histologically normal 
Adult Lman1-/- (A) kidney, (B) heart, (C) lung, and (D) liver tissues were evaluated by a 
pathologist blinded to mouse genotype.  Images were taken using an Olympus BX43 
microscope and an Olympus DP72 camera.  Kidney and lung images are magnified 40X, 
heart and liver are 60X. 
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CHAPTER 4 : 
PROTEOMIC APPROACHES TO IDENTIFY NOVEL LMAN1 FUNCTIONS 
 
Note:  Chapter 4 is a summary of our attempts to identify novel LMAN1 and MCFD2 
interacting proteins through a number of in vitro and in vivo techniques.  All experiments 
were performed by Lesley Everett.  The Y2H assay was performed in collaboration with 
the Rual laboratory (UM Pathology).  Mass-spectrometry was performed at the UM 
Pathology Department Proteomics facility, and bioinformatics analysis of the mass-
spectrometry data was performed in collaboration with the Nesvizhskii laboratory (UM 
Pathology). 
 
 
INTRODUCTION 
 
Proteomic analysis of the secretory pathway 
The protein secretory pathway is comprised of a number of specialized organelles 
essential for the folding, modification, and transport of secreted and membrane-bound 
proteins.  Selective receptor-mediated ER-to-Golgi protein transport plays an important 
role in this pathway, but many of the protein-protein interactions and regulatory 
mechanisms utilized by ER cargo receptors are poorly defined.  In particular, very little is 
understood about the specificity with which these receptors identify and recruit protein 
cargos from the ER lumen into budding COPII vesicles.67,146  Furthermore, the 
mechanisms by which cargo receptors interact with cytoplasmic COPII vesicle 
components to facilitate proper cargo sorting are not well understood.  It is likely that 
protein-protein interactions on both sides of the ER membrane affect the function of these 
ER cargo receptors.  For example, SEC24 is the COPII coat component that interacts 
with transmembrane cargos and receptors in yeast and mammalian cells, and the 
transmembrane proteins serve as the communicating link between the inside and outside 
of COPII vesicles.  Mammals have four SEC24 paralogs (A-D), and they are presumed to 
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fulfill distinct temporal or tissue-specific roles in the transport of protein cargos.  This is 
consistent with the finding that mutations in individual COPII coat paralogs result in 
specific and distinct cellular defects and clinical disorders (Table 4-1).67,147,148  These 
phenotypes may be due directly to the impaired secretion of a SEC24-specific 
transmembrane protein cargo.  Alternatively, as in the case of SEC24A and the soluble 
PCSK9 cargo,149 the defect may result from the impaired recruitment of an ER cargo 
receptor and its complement of soluble cargos (the ER cargo receptor for PCSK9 has yet 
to be identified).  It is possible that the specific combination of SEC23 and SEC24 
paralogs in a COPII coat may determine which ER cargo receptors and cargos are 
recruited into a budding vesicle.  Although there is high-quality structural data revealing 
the general COPII coat framework and lattice structure,150-156 little is known about the 
spectrum of possible interactions and potential binding preferences between the COPII 
coat component paralogs.  The factors that determine the specific composition of COPII 
coat component paralogs in a given COPII vesicle are also unknown. 
 
A more comprehensive understanding of the dynamic protein-protein interactions in ER-
to-Golgi transport is required both to identify new cargo/receptor pairs and to identify the 
factors that determine which receptors and cargos are recruited into each COPII 
vesicle.157  Numerous sensitive proteomic and bioinformatics techniques are now 
available to detect transient protein-protein interactions and to quantify impaired 
trafficking through the secretory pathway, complementing classical methods in genetics 
and molecular cell biology.158-162  Quantitative proteomic methods such as SILAC, 
isotope-coded affinity tags, isobaric labeling, and label-free quantification can be used to 
determine quantitative differences in the abundance of protein cargos in different 
secretory compartments.  High-throughput versions of classic genetic assays such as 
yeast two-hybrid (Y2H), fluorescent protein fragment complementation assays, and the 
split-ubiquitin method have been developed and are also suitable for these purposes.163  
These proteomic methods offer an unbiased, proteome-wide approach by which to dissect 
the components of the secretory pathway and the relationships among them.  Most of 
these strategies have not yet been applied to the study of receptor-mediated cargo 
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transport and COPII vesicle trafficking.  Such work will provide valuable insights into 
the function and regulation of ER cargo receptors. 
 
Applications to the study of LMAN1 biology 
Nearly 8,000 proteins traffic through the mammalian secretory pathway, and the majority 
are thought to rely on specialized ER cargo receptors for recruitment into COPII vesicles.  
It is therefore surprising that LMAN1/MCFD2 is the only known mammalian ER cargo 
receptor complex, and that only a handful of LMAN1-dependent cargos are known.  
LMAN1/MCFD2 functions to selectively recruit cargo proteins into budding COPII 
vesicles at the ER membrane for anterograde transport to the Golgi apparatus.  The best 
characterized LMAN1-dependent secretory cargos are FV and FVIII, and three less 
characterized LMAN1 cargos are A1AT and cathepsins C and Z (CTSC, CTSZ).85,164  
Several lines of evidence suggest that additional LMAN1 cargos and MCFD2-like 
adaptors remain to be discovered, as well as novel ER cargo receptors for secretion of 
other proteins.  Mass-spectrometry analyses and proteomic profiling of secretory 
organelles, plasma membranes, and secreted proteins from wild-type and LMAN1-
deficient mice should facilitate the identification of novel LMAN1 cargos.  The 
identification of novel LMAN1-dependent cargos and interacting proteins is of 
fundamental importance for elucidating other proteins that may contribute to F5F8D 
pathophysiology, and for understanding the ubiquitous and essential cellular process of 
protein secretion.  
 
Previous characterization of LMAN1’s protein-protein interactions and cargo selectivity 
relied on traditional methods such as crosslinking and immunoprecipitation or fluorescent 
complementation assays.40,85,164  The limited scope and focus of these studies precluded 
the global identification and interrogation of LMAN1’s full complement of binding 
partners.   A global proteomics-based approach offers an unbiased method by which to 
identify additional LMAN1/MCFD2 cargos.  A number of valuable reagents are available 
for this work, including in vitro and in vivo F5F8D models.  The currently known 
LMAN1 cargos should serve as convenient “built in” positive controls.  In the absence of 
LMAN1, its dependent cargos are expected to accumulate in the ER and to be 
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underrepresented in the Golgi or other post-Golgi compartments such as lysosomes, the 
plasma membrane, and secreted proteins.   Quantifiable differences in LMAN1 cargo 
abundance in downstream secretory compartments of wild-type and LMAN1 deficient 
mice should be detectable by mass-spectrometry.   
 
The identification of new LMAN1 cargos may provide insights into the binding motif 
and/or the specific recognition sequence utilized by LMAN1 for cargo recruitment, and 
this in turn may be used to predict other novel LMAN1 cargos based on protein sequence 
and structure.  There is no clear homology sequence or structural domain shared between 
the five known LMAN1 cargos (FV, FVIII, A1AT, CTSC, CTSZ).  The only other 
protein with sequence homology to FV and FVIII is ceruloplasmin, a copper-binding 
glycoprotein involved in iron transport across the cell membrane.  FV, FVIII, and 
ceruloplasmin are evolutionarily related structures that likely resulted from duplications 
of ancestral precursor genes.165  FV and FVIII share the protein domain structure A1-A2-
B-A3-C1-C2, and ceruloplasmin contains three FV/FVIII type A domains.  The A 
domains of FV and FVIII display ~30% sequence identity, and there is a comparable 
sequence identity (38-42%) between the FV and ceruloplasmin A1, A2, and A3 domains. 
 
Preliminary characterization of samples from Lman1gt1/gt1 mice was performed in our lab 
using a mass spectrometry-based approach (unpublished work).166  Isobaric tags (iTRAQ 
reagents) were used to quantitatively analyze proteins from plasma, pancreatic zymogen 
granules, and lectin-affinity purified liver tissue lysates.  Although these preliminary 
analyses presented technical challenges, results suggested that differences between the 
protein “secretome” of Lman1gt1/gt1 and wild-type mice should allow us to identify 
additional LMAN1-dependent cargo proteins.166  
 
Considering LMAN1’s protein-protein interactions on the cytoplasmic side of the ER 
membrane, little is known about the factors regulating its interactions with the COPII 
coat for recruitment into budding vesicles.  LMAN1’s cytosolic tail domain contains a di-
phenylalanine ER-exit motif (FF) for recruitment into vesicles by the SEC24 COPII coat 
component.  Four mammalian SEC24 paralogs exist (A-D), and it is unknown whether 
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LMAN1 physically interacts with all 4 paralogs.  However, Wendeler et al. reported that 
siRNA knockdown of each SEC24 paralog individually in HeLa cells had no effect on 
the ER-to-Golgi transport of LMAN1, implying that LMAN1 does not have a strong 
binding preference (or dependence) upon a specific SEC24 paralog for recruitment into 
COPII vesicles.167  Similarly, it is unknown whether the specific combination of COPII 
coat components determines the content of the trafficking vesicle.  As a first step in 
addressing this question, it is necessary to determine the different possible binding 
combinations of the COPII coat component paralogs, particularly between the inner coat 
components SEC23 (SEC23A and SEC23B) and SEC24 (SEC24 A-D). 
 
Preliminary attempts to address these questions, and to identify novel LMAN1 cargos, 
were performed with a combination of in vitro experiments as well as cell-fractionation 
and mass-spectrometry studies. 
 
 
MATERIALS AND METHODS 
 
Cell culture and co-immunoprecipitation 
COS cells were cultured in DMEM (Gibco) supplemented with 5% FBS and 1% pen-
strep (Gibco) according to standard protocols.  Cell transfections were performed with 
FuGENE HD transfection reagent (Promega) according to the manufacturer’s 
instructions.  Expression vectors encoding the following epitope-tagged murine proteins 
were used:  RFP-SEC24A, RFP-SEC24B, RFP-SEC24C, RFP-SEC24D, FLAG-
SEC23A, FLAG-SEC23B, and FLAG-LMAN1.  Study of the interactions of LMAN1 
and the SEC24 paralogs was performed by co-transfecting FLAG-LMAN1 individually 
with each of the RFP-tagged SEC24 constructs.  Similarly, interactions between the 
SEC23 and SEC24 paralogs were explored by co-transfecting each FLAG-tagged SEC23 
construct individually with each RFP-tagged SEC24 construct.  DSP crosslinking 
(Pierce) of cell lysates was performed for 30 minutes at 4°C according to the 
manufacturer’s instructions.  Anti-FLAG and anti-RFP immunoprecipitations were 
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performed with EZview Red ANTI-FLAG M2 affinity gel beads (Sigma) and agarose 
conjugated anti-RFP beads (MBL International), respectively, according to the 
manufacturer’s instructions. 
 
Western blots 
Antibodies used in Western blotting experiments are: a polyclonal antibody against RFP 
(Abcam), a polyclonal antibody against FLAG (Cell Signaling), a monoclonal antibody 
against GM130 (Santa Cruz Biotechnology), a polyclonal antibody against Erp44 (Cell 
Signaling), a polyclonal antibody against EEA1 (Abcam), a polyclonal antibody against 
LAMP-1 (Developmental Studies Hybridoma Bank), a monoclonal antibody against 
Complex II (Invitrogen), a polyclonal antibody against Annexin V (Cell Signaling), and a 
polyclonal antibody against ceruloplasmin (Abcam).  
 
Yeast two-hybrid 
In collaboration with Dr. Jean-François Rual (University of Michigan Department of 
Pathology), a high-throughput Y2H experiment168-170 was performed to identify novel 
LMAN1 and MCFD2 interacting proteins.  Three protein fragments of interest were 
cloned into the pDest22 and pDest32 Invitrogen Gateway Recombination cloning vectors 
according to the manufacturer’s instructions in order to generate Gal4 DNA-binding 
domain (DB-X) and Gal4 activation domain (AD-Y) hybrid proteins.  The three protein 
fragments that were tested are shown in Figure 4-1 and include: (1) the LMAN1 luminal 
domain without signal peptide, (2) the LMAN1 cytoplasmic tail, and (3) MCFD2 without 
signal peptide.  The library of potential interacting proteins used by the Rual laboratory 
for all high-throughput Y2H screens is a human ORFeome library (v5.1), a cloned set of 
protein-encoding open reading frames representing approximately 11,200 human 
genes.171,172  Relevant positive controls included in this hORFeome library are MCFD2, 
FVIII, and A1AT.  The three protein fragments of interest were tested by Y2H in a 
primary screening in the DB-X conformation (protein fragment as “bait”) against mini-
libraries, each containing a pool of 12 AD-Y fusion proteins, by yeast-mating in 96-well 
format.  As a secondary screening, the DB-X proteins were tested individually against 12 
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AD-Y fusions of each mini-pool, for those mini-pools in which hits were observed in the 
primary screening.  The detailed methods, experimental controls, and validation steps for 
this high-throughput Y2H platform were previously described.169   
 
Lman1 deficient mice 
Lman1-/- mice (described in Chapter 3) were used as the source of plasma and tissue 
samples for several proteomic experiments.  Plasma samples from Lman1-/- mice and 
wild-type controls were collected and snap frozen as described in Chapter 2.  Equal 
volumes of mouse plasma from individual animals were run on Novex Bis-Tris 4-12% 
gels (Invitrogen) with MOPS buffer (Invitrogen), and the gels were subsequently stained 
with SYPRO Ruby Protein Gel Stain (Invitrogen) for fluorescent protein detection 
according to the manufacturer’s instructions.  Gels were imaged on a Typhoon 9410 
Molecular Imager (Amersham Biosciences).  Western blot analysis of murine plasma 
samples was performed by SDS-PAGE and transfer to nitrocellulose membranes.  
Tissues were collected as described in Chapter 3, except that samples were processed 
immediately (see “Cell Fractionation”) rather than frozen.  Mouse liver tissue samples 
were prepared from two mice per genotype.  Littermate controls were used to reduce the 
potential effects of different diet, age, and housing conditions between experimental 
mice.     
 
Cell fractionation 
Collaborations with several University of Michigan faculty members (Yanzhuag Wang, 
Haoxing Xu, and Alexey Nesvizhskii) were established to optimize secretory organelle 
purification techniques and to conduct bioinformatics analyses of proteomics data.  
Standard differential density centrifugation protocols for ER, Golgi, and lysosome 
fractions of cultured cells and murine tissues were utilized.173-175  Since two known 
LMAN1 cargos are lysosomal cathepsins (CTSC and CTSZ) and could therefore serve as 
a positive control in the cell fractionation prep, in preliminary studies we focused on the 
optimization of lysosome purification from mouse liver tissues.  Multiple variables were 
tested in the optimization of this protocol, including fresh vs. frozen liver samples, the 
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extent of tissue homogenization, the volume of post-nuclear supernatant applied to the 
gradient, and the storage conditions of the final isolated lysosome prep.  Briefly, samples 
were homogenized and lysed in HM Buffer (0.25M sucrose, 1mM EDTA, 10mM 
HEPES, pH 7.0), and the resulting lysate was centrifuged at 4200 rpm for 10 minutes at 
4°C.  The post-nuclear supernatant was applied to an 18% Percoll (Sigma) solution in 
HM buffer and centrifuged for 1 hour at 31,300 rpm at 4°C to separate the membrane 
fractions into light, medium, and heavy populations.  The heavy membrane population 
was centrifuged again at 14,000 rpm for 10 minutes to concentrate and pellet the 
remaining organelles, which were subsequently applied to an Iodixanol (Sigma) gradient 
(8-27%) to separate lysosomes and mitochondria (the two primary components of the 
heavy membrane fraction).  The resulting Iodixanol gradient fractions were analyzed by 
Western blot for relative abundance of lysosome and mitochondrial content, and the 
fractions with the highest enrichment for lysosomal proteins were applied to SDS-PAGE 
gels for electrophoresis.  Gel lanes were cut into 5-8 pieces and submitted for mass-
spectrometry. 
 
Protein Identification by LC-Tandem Mass-spectrometry 
Mass-spectrometry analysis was performed at the Fred Hutchinson Cancer Research 
Center Proteomics Facility or at the University of Michigan Molecular Diagnostics 
Laboratory.  Purified samples (lysosome fractions or platelet-poor plasma) were resolved 
on a SDS-PAGE and proteins visualized using Colloidal Coomassie stain.  Unique bands 
were excised and destained with 30% methanol for 4 h.  Upon reduction and alklylation 
of the cysteines, proteins were digested overnight with sequencing grade, modified 
trypsin (Promega).  Resulting peptides were resolved on a nano-capillary reverse phase 
column (Picofrit column, New Objective) using a 1% acetic acid/acetonitrile gradient at 
300 nl/min and directly introduced in to a linear ion-trap mass spectrometer (LTQ XL, 
ThermoFisher).  Data-dependent MS/MS spectra on the 5 most intense ion from each full 
MS scan were collected (relative CE ~35%).  Proteins were identified by searching the 
data against Human IPI database (v 3.41) appended with decoy (reverse) sequences using 
X!Tandem/Trans-Proteomic Pipeline (TPP) software suite.  All proteins with a 
ProteinProphet probability score of >0.8 (error rate <1%) were considered positive 
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identifications and manually verified.  Only proteins with 2 or more unique peptides were 
included in the analysis.  The Abacus computational tool for spectral count data for label-
free quantitative proteomic analysis was used to normalize the spectral count data from 
each of the plasma band samples.176  Preliminary statistical analysis of the normalized 
spectral counts was performed with a student’s t-test, with p < 0.05 considered 
statistically significant.  For a more appropriate and useful analysis of this data, the 
normalized spectral counts for the plasma samples were also submitted to QSPEC 
(http://www.nesvilab.org/qspec.php/), a software program for the analysis of differential 
protein expression/abundance using label-free spectral count data.  QSPEC calculates the 
ratio of likelihoods (Bayes Factor) for differential expression/abundance for each protein 
based on certain model assumptions (Poisson-family distributions for count data and 
Gaussian distributions for intensity data).  The QPSEC method is more appropriate than 
conventional statistic-based tests such as the t-test for our data given that there are only 
three replicate samples per genotype.  
 
As part of my graduate training, I completed a graduate course in Proteome Informatics 
(taught by Dr. Alexey Nesvizhskii), as well as a weeklong proteomics and mass-
spectrometry course at the Fred Hutchinson Cancer Research Center Proteomics Facility.  
 
 
RESULTS 
 
LMAN1 interacts with all four mammalian SEC24 paralogs 
As demonstrated by co-expression and co-immunoprecipitation experiments in vitro, 
LMAN1 physically interacts with all four murine SEC24 paralogs (A-D) in 
approximately equal proportion (Figure 4-2).  Similarly, both murine SEC23A (Figure 
4-3A) and SEC23B (Figure 4-3B) paralogs physically interact with each of the four 
murine SEC24 paralogs (A-D), also in essentially equal proportions.  Therefore, eight 
possible SEC23-SEC24 combinations are available for the generation of the heterodimer 
pairs that compose the inner COPII coat membrane (SEC23A-SEC24A, SEC23A-
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SEC24B, SEC23A-SEC24C, SEC23A-SEC24D, SEC23B-SEC24A, SEC23B-SEC24B, 
SEC23B-SEC24C, SEC23B-SEC24D).   
 
Novel LMAN1/MCFD2 interacting proteins were not identified by yeast two-hybrid 
Protein fragments corresponding to the LMAN1 luminal domain, the LMAN1 cytosolic 
tail domain, and the MCFD2 protein were tested in a high throughput Y2H assay against 
a human ORFeome library of potential interacting proteins.  In the primary screening of 
each fragment against mini-pools of 12 ORFs per pool, five potential hits were identified 
for the LMAN1 cytosolic domain.  The identify of these potential interacting proteins 
was not determined in the primary screen because the ORFs are screened in groups of 12; 
one of the ORFs in a mini-pool of 12 ORFs was responsible for each of the primary 
screen hits.  However, upon more stringent secondary screening of the LMAN1 cytosolic 
tail domain individually against each member of the ORF mini-pools for direct binary 
interactions, no hits were confirmed.  The secondary screening was performed twice to 
confirm this result.  No hits were identified in the primary screening for either the 
LMAN1 luminal domain or the MCFD2 fragment.  Of note, no known “positive control” 
protein-protein interactions were identified in this Y2H screen, including LMAN1-
MCFD2 interactions, LMAN1-FVIII interactions, MCFD2-FVIII interactions, or 
LMAN1-A1AT interactions. 
 
Comparison of serum proteins in wild-type and Lman1-/- mice 
Platelet-poor plasma from wild-type and Lman1-/- mice was compared by SDS-PAGE, 
and a protein of ~ 100 kDa molecular weight was observed to be of lower abundance 
(~50% or less than observed in wild-type) in Lman1-/- mouse plasma samples as 
compared to that of wild-type samples (Figure 4-4).  Since ceruloplasmin, a potential 
candidate LMAN1 cargo with homology to FV and FVIII, is also ~100 kDa, we 
compared its abundance in the plasma of wild-type and Lman1-/- mice by Western blot.  
Plasma ceruloplasmin levels were indistinguishable between wild-type and Lman1-/-  mice 
(Figure 4-5).  The ~100 kDa band of interest (indicated by a black arrow in Figure 4-4) 
was excised from three wild-type and three Lman1-/- lanes for mass-spectrometry 
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analysis.  The normalized spectral counts for each of the 24 proteins that were detected in 
3 or more of the six excised gel bands are listed in Table 4-2.  Based on a preliminary 
comparison of the spectral counts for each protein in Lman1-/- vs. Lman1+/+ samples (by 
t-test), only one protein in the list, SERPINA3K, was found to have a statistically 
significantly lower number of spectral counts in the Lman1-/- plasma samples as 
compared to the wild-type plasma samples (p < 0.05).  Complement Component C3 was 
also marginally significantly reduced in Lman1-/- plasma samples as compared to wild-
type samples.  For a more appropriate and computationally rigorous analysis, the 
normalized spectral counts for the plasma proteins were also analyzed by QSPEC.  
According to QSPEC, SERPINA3K and Complement Component C3 were both highly 
significantly under-represented in the Lman1-/- plasma samples as compared to the wild-
type samples (Table 4-3), and these were the only two proteins that were under-
represented in the Lman1-/- plasma samples.  To further investigate these proteins as 
putative LMAN1 cargos, we are currently comparing the abundance of SERPINA3K and 
C3 in wild-type and Lman1-/- mouse plasma samples by Western blot.   
 
Optimization of cell fractionation and organelle isolation 
Lysosome isolation (Figure 4-6A) from cultured cells (not shown) and mouse tissues was 
optimized.  Cellular membrane fractions were successfully separated by differential 
density centrifugation such that lysosome-enriched, mitochondrial-depleted fractions 
were consistently isolated (Figure 4-6B).  When these lysosome-enriched fractions were 
pooled and then subjected to Western blot analysis to confirm the enrichment and purity 
of the sample, the preps were demonstrated to be highly enriched for lysosomal proteins 
and largely free of golgi, ER, endosome, mitochondrial, and plasma membrane protein 
contaminants (Figure 4-7).  The purified lysosome samples were separated by SDS-
PAGE (Figure 4-8) and were submitted for mass spectrometry analysis.  Data analysis 
was performed with Dr. Alexey Nesvizhskii’s bioinformatics laboratory at the University 
of Michigan.177,178  Unfortunately, despite the high lysosomal enrichment and the lack of 
other cellular contaminants observed for these lysosome preps by Western blot analysis 
(Figure 4-7), bioinformatics analysis of the mass-spectrometry data revealed a surprising 
relatively small number of distinct lysosomal proteins as compared to other membrane-
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associated and secretory proteins in these submitted samples.  Several well-established 
lysosomal marker proteins were not detected in the samples, or detected at very low 
abundance.  For example, only 3-5 spectral counts were identified in each sample for 
lysosome-associated membrane glycoprotein-1 (LAMP1), and only 5-6 spectral counts 
were identified in each sample for lysosome-associated membrane glycoprotein-2 
(LAMP2).  Similarly, both wild-type and Lman1-/- samples had a comparable low number 
of spectral counts for cathepsin Z (1-2 counts), cathepsin H (2-3 counts), and cathepsin D 
(5-16 counts).  Cathepsin C was not detected in either the wild-type or Lman1-/- samples.  
The low abundance of lysosomal proteins and the presence of numerous other secretory 
proteins (many of which do not have cellular localization information listed in the protein 
databases) precluded the meaningful statistical comparison of these samples and the 
identification of any lysosomal proteins that were potentially differentially secreted in 
wild-type and Lman1-/- mice. 
 
 
DISCUSSION  
 
A combination of simple in vitro experiments and more technically challenging cell-
fractionation and mass-spectrometry studies were performed for the purpose of 
identifying novel LMAN1-dependent secretory cargos, and to characterize LMAN1’s 
interactions with the inner layer of COPII vesicle coats.  These experiments were met 
with variable success, and emphasize that in order to develop a complete picture of 
LMAN1’s interacting partners and dependent secretory cargos, we will likely require the 
detection of subtle quantitative differences in protein trafficking and the identification of 
transient protein interactions within secretory compartments.   
 
We initially demonstrated by co-immunoprecipitation that LMAN1 physically interacts 
with all four mammalian SEC24 paralogs in approximately equal proportion.  This 
finding suggests that the recruitment of LMAN1 and its cargos to budding COPII vesicles 
via interaction with the SEC24 COPII coat component is not likely a selective sorting 
step.  This finding is consistent with the results of Wendeler et al.’s siRNA knockdown 
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of the SEC24 paralogs, which revealed no difference in ER-to-Golgi transport of 
LMAN1 in the absence of any individual SEC24 paralog.167  Although LMAN1 does not 
demonstrate any SEC24 binding specificity, it is possible that other ER cargo receptors 
do use SEC24 binding as a sorting mechanism.  We also demonstrated by co-
immunoprecipitation that 8 possible SEC23-SEC24 heterodimer building blocks are 
available for the synthesis of new COPII vesicles.  SEC23A and SEC23B are both able to 
form heterodimers with all four SEC24 paralogs (A-D).  The biologic significance and 
functional differences between these 8 different SEC23-SEC24 heterodimer pairs is 
currently unknown.  However, given the highly specific and distinct phenotypes that 
result from deficiency of these individual COPII coat component paralogs (Table 4-1), it 
is clear that these proteins (and perhaps the combinations in which they interact) play 
critical and complex roles in protein secretion that are essential for the maintenance of 
cell function.149,179-182  Since LMAN1 binds all four SEC24 paralogs, it presumably binds 
all 8 heterodimer pairs, although we did not test this directly. 
 
A Y2H assay was performed in collaboration with the Rual laboratory (UM Pathology 
Department) to identify novel LMAN1 and MCFD2 interacting proteins.  Although the 
Y2H approach has its own technical limitations, especially for transmembrane proteins, 
recent advances in the field have enabled the development of high-quality, efficient, and 
reliable binary protein-protein interactome mapping strategies.183,184  Y2H has led to the 
characterization of thousands of binary protein interactions and has been extremely useful 
for interrogating developmental and disease mechanisms.  The Rual laboratory utilizes a 
unique Y2H protein interaction mapping platform169 that can be used in both 1) the 
discovery mode to uncover new protein interactors and novel molecular mechanisms in 
which the proteins of interest are involved; and 2) the validation mode to dissect the 
molecular architecture of specific protein complexes by systematically testing pairs of 
interactors and by refining the precise molecular organization of the protein complexes, 
i.e., determining which proteins (or domains) interact directly with each other in a given 
complex.  Dr. Rual’s laboratory has utilized this platform to systematically screen 25 
million pairs of proteins for their ability to physically interact with each other, resulting 
in the detection of 2,800 high-quality Y2H protein interactions.   
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Though these methods would seem ideal for the purpose of identifying and confirming 
novel LMAN1- or MCFD2- interacting proteins, we did not detect any reproducible 
interactions that passed the second, more stringent screening test for either LMAN1 or 
MCFD2.  Similarly, no known LMAN1 interacting proteins (MCFD2, FVIII, or A1AT) 
were identified in this screen.  This negative result is not unexpected, given that Y2H is 
not an extremely sensitive method, and typically only about half of the baits tested 
generate a hit in the primary screen.185  Also, Y2H has a low sensitivity for membrane 
proteins.186  Since Y2H is based upon the reconstitution of a transcription factor, all 
protein-protein interactions must occur within the nucleus.  Membrane proteins must 
therefore be tested in fragments (each as a DB-X or AD-Y fusion) that localize to the 
nucleus.  As a result, some membrane protein fragments are misfolded or lack critical 
domains or residues necessary for their endogenous protein-protein interactions.  
Differences between the nuclear environment and the membrane protein’s endogenous 
cellular location may prevent it from interacting with binding partners.  In the case of 
LMAN1 and MCFD2, it is likely that the nuclear environment is insufficient to allow the 
protein-protein interactions that usually take place within the ER lumen. 
 
Another high throughput strategy to identify protein-protein interactome networks in a 
more direct manner is affinity purification followed by mass spectrometry (AP-MS), 
which detects biochemically stable, copurifying protein complexes.  Both direct and 
indirect protein associations may be detected by AP-MS.  However, AP-MS is not well 
suited to membrane proteins, which are particularly difficult to isolate due to their 
hydrophobic nature.  In addition, the biochemical isolation of membrane proteins such as 
LMAN1 usually disturbs any associated proteins in complex with the membrane 
protein.187 
 
In addition to these in vitro experiments, our LMAN1 deficient mouse models serve as a 
valuable resource for proteomics samples, particularly the plasma and secretory tissues.  
We separated platelet-poor plasma samples by SDS-PAGE and observed an ~100 kDa 
band that was visibly lower in abundance in the plasma of Lman1-/- mice as compared to 
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wild-type mice.  This band could potentially correspond to a plasma protein that depends 
on LMAN1 for secretion (i.e. a novel cargo).  It could also potentially represent a protein 
which is differentially present in the Lman1-/- plasma samples as an indirect result of 
LMAN1 deficiency, but that is not an LMAN1 cargo itself.   
 
Considering the major plasma glycoproteins of ~100 kDa molecular weight, 
ceruloplasmin was the most obvious potential LMAN1 cargo candidate.  Ceruloplasmin 
shares a significant sequence and domain structure homology with FV and FVIII.  
However, plasma ceruloplasmin levels were indistinguishable between wild-type and 
Lman1-/- mice.  Ceruloplasmin does not contain a glycosylated B domain (as do FV and 
FVIII), and the B domain has been shown to be required for efficient LMAN1-FVIII 
interactions,42 potentially explaining why ceruloplasmin is not also an LMAN1 cargo.   
Consistent with our data, it was previously shown that ceruloplasmin does not co-
immunoprecipitate with LMAN1 or MCFD2.32,42  In addition, low plasma ceruloplasmin 
levels have not previously been reported in F5F8D patients.188 
 
In order to identify the ~100 kDa protein of interest and to determine if there is a 
statistically significant difference in its abundance in the plasma between wild-type mice 
and Lman1-/- mice, three gel bands for each genotype were submitted for LC-MS/MS 
analysis.  Of the ~30 proteins reliably detected in 3 or more of the 6 submitted samples, 
only two proteins demonstrated a statistically significant difference between the wild-
type and the Lman1-/- samples (Table 4-3).  The first protein that was detected in 
significantly lower abundance in Lman1-/- samples as compared to Lman1+/+ samples was 
SERPINA3K, also known as serine protease inhibitor A3K.  Serine protease inhibitors 
(otherwise known as SERPINS) are highly abundant in the plasma, and most are targeted 
toward the serine proteases involved in phagocytosis, coagulation, complement 
activation, and fibrinolysis.  We would expect this SERPIN to likely be identified in 
complex with its target protease, since protease:protease inhibitor complexes are 
irreversibly bound and would remain in complex on an SDS-PAGE gel.  Therefore, we 
would expect that SERPINA3K’s target protease could also potentially be identified in 
the mass-spectrometry samples.  Consistent with this expectation, the second under-
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represented protein in the Lman1-/- plasma samples was Complement Component C3, a 
serine protease.  As far as we are aware, SERPINA3K and Complement Component 3 are 
not known to function together, but many protease:protease inhibitor combinations are 
not currently known, or have been inaccurately catalogued.  
 
 
SERPINA3K is a particularly interesting candidate LMAN1 cargo.  It is a member of the 
“clade A” serpins, which comprises alpha-1 antitrypsin (SERPINA1) and alpha-1 
antichymotrypsin (SERPINA3).  Whereas alpha-1 antitrypsin and alpha-1 
antichymotrypsin are each encoded by a single gene in humans, in the mouse they are 
represented by clusters of 5 and 14 genes, respectively, resulting from multiple gene 
duplication events.189  Of interest, alpha-1 antitrypsin (SERPINA1) is one of LMAN1’s 
reported cargo proteins, in addition to FV and FVIII.85  The duplication and divergence of 
these clade A SERPINS in mice as compared to humans (and their potential differences 
in LMAN1-dependent secretion) represent an intriguing possible explanation for the 
different phenotypes observed in mice and humans with LMAN1 deficiency.  To further 
assess SERPINA3K and/or Complement Component C3 as putative LMAN1 cargos, we 
are currently comparing the abundance of SERPINA3K and C3 in wild-type and Lman1-/- 
plasma samples and liver lysates.             
 
Finally, our preliminary attempts at cell fractionation and secretory organelle isolation for 
mass-spectrometry were uninformative, and further optimization is required before we 
can put this approach into practice.  For example, as demonstrated by Western blot 
analysis, the lysosome isolation protocols we utilized resulted in highly enriched, nearly 
pure lysosomal fractions that appeared to be of sufficient purity and enrichment for useful 
mass-spectrometry analysis.  However, the protein identifications resulting from these 
samples demonstrated surprisingly few lysosomal proteins, and were convoluted by many 
other non-lysosomal secretory and membrane proteins.  In the future, it may be useful to 
develop a more stringent standard for ensuring that the lysosome fractions are free of 
other cellular contaminants.  In addition, we may consider using exclusively cultured 
cells rather than animal tissues for organelle isolations, since this is a cleaner system for 
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cell fractionation.  However, the limitations of using an in vitro rather than in vivo system 
include the fact that (1) cells cultured in vitro may behave differently in a culture dish 
than in the physiologic context of an entire organism, (2) in vitro culture is an artificial 
system in which cells are not exposed to the same signals and stimuli as they are in the 
context of living organisms (i.e. cytokines and hormone signaling, sheer stress and flow 
conditions in a vessel, etc.), and (3) in vitro culture conditions cannot capture inter-
animal variation. 
 
Given that the protein secretion defect in LMAN1-deficient mice (and in humans with 
LMAN1 mutations) is expected to vary between individuals (see Chapter 3), we 
ultimately need a precise and sensitive method by which to detect and quantify 
potentially subtle defects in protein transport.  One approach that would provide 
quantitative information about the relative abundance of potential LMAN1 cargos in the 
secretory pathway is SILAC labeling190 (stable isotope labeling by amino acids in cell 
culture), which provides highly accurate quantitation for cells grown in culture160 as well 
as for metabolic labeling of whole animals.191  By feeding mice a special diet containing 
either the natural 12C6-lysine or lysine substituted with a non-radioactive stable isotope 
(13C6-lysine), it is possible to differentially label samples for quantitative MS/MS 
analysis.  Our lab has successfully used SILAC in cell culture, and we have also 
generated a set of 13C6-lysine wild-type C57BL/6J mice that may be used as controls for 
quantitative MS/MS comparisons with Lman1-/- mice in the future. 
 
Subsequently, any putative LMAN1-dependent cargos will be experimentally validated to 
demonstrate cellular co-localization with LMAN1 (immunohistochemistry, 
immunofluorescence) as well as physical cargo-receptor interactions 
(immunoprecipitation and quantitative western blots, chemical crosslinking).  In addition, 
several experimental models of F5F8D (including knockout mice, immortalized patient 
lymphocyte cell lines, Lman1-/- murine embryonic fibroblasts, and a dominant-negative 
LMAN1 cell line) are available to assess and quantify impaired trafficking of putative 
cargos of interest.  The dominant-negative LMAN1 is a mutant form of LMAN1 that is 
incapable of leaving the ER.87  In cells expressing this dominant-negative mutant, known 
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and novel LMAN1 cargos would be expected to accumulate in the ER (and to be under-
represented in downstream secretory compartments) as compared to their localization in 
cells expressing wild-type LMAN1.    
 
We anticipate that in the future, with further optimization of cell fractionation, it will be 
possible to compare the proteome of purified ER, Golgi, lysosome, plasma membrane, 
and secreted proteins for wild-type mice, Lman1-/- mice, Mcfd2-/- mice, and doubly 
deficient Lman1-/-, Mcfd2-/- mice.  We expect to identify new cargos that rely on LMAN1 
for efficient ER-to-Golgi transport. We also expect to confirm several previously 
suspected or poorly characterized LMAN1 cargos such as CTSC, CTSZ, and A1AT. 
 
Such work will be necessary to elucidate LMAN1’s complete role in the secretory 
pathway.  Further, it will provide a model for understanding selective receptor-mediated 
transport by other ER receptors, and will help explain why defects in protein trafficking 
lead to disease.  
 
Notable challenges still remain in the field of organelle proteomics, such as how to most 
accurately measure changes in protein distribution under different cellular conditions or 
genetic backgrounds.  However, technological and analytic advances in organellar 
proteomics have increased the reliability and resolving power of MS-based studies.  
Ultimately, these advances will enable us to make unbiased, proteome-wide 
characterizations of organellar proteomic profiles and to develop a more comprehensive, 
accurate picture of the subcellular localization of entire proteomes under different 
experimental conditions.158  These developments have important basic science 
implications, as well as clinical and translation relevance.  Ultimately, the proteomic 
characterization of secretory organelles and of ER receptor/cargo pairs may enable the 
therapeutic restoration of individual pathway defects to alleviate a wide range of human 
inherited diseases associated with protein misfolding and trafficking, including 
F5F8D.147,158 
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Table 4-1:  Congenital disorders of the early secretory pathway 
Type S. cerevisae Mammal Human disease or Mouse Phenotype 
COPII vesicle 
Sar1p Sar1a Sar1b 
Embryonic lethal (E<10.5) 
CRD; Lethal by weaning 
Sec23p Sec23a Sec23b 
CLSD; Embryonic lethal 
CDAII: Perinatal lethality 
Sec24p 
 
Lst1p 
Iss1p 
Sec24a 
Sec24b 
Sec24c 
Sec24d 
Low cholesterol 
Late embryonic lethal, neural tube defect 
Early embryonic lethal 
Early embryonic lethal 
Sec13p Sec13 None known 
Sec31p Sec31a Sec31b 
None known 
None known 
Cargo 
receptor/adaptor 
NA Lman1 F5F8D: F5F8D, perinatal lethality 
NA Mcfd2 F5F8D; F5F8D 
CRD, Chylomicron retention disease; CLSD, Cranio-lenticulo-sutural dysplasia; CDAII, Congenital 
dyserythropoietic anemia type II; F5F8D, Combined deficiency of coagulation factors V and VIII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
Table 4-2:  Spectral counts for proteins identified in excised gel bands from mouse 
plasma samples 
Protein Lman1
-/- 
(#1) 
Lman1-/- 
(#2) 
Lman1-/- 
(#3) 
Lman1+/+ 
(#1) 
Lman1+/+ 
(#2) 
Lman1+/+ 
(#3) 
p-
value 
ITIH3 9.805 3.793 0.000 2.619 0.000 0.000 0.287 
C4B 2.629 0.000 2.243 3.687 2.349 2.975 0.203 
A2M 22.738 8.210 21.556 22.474 26.407 26.078 0.196 
CFH 6.174 3.981 7.024 9.896 7.354 5.590 0.289 
FGA 10.134 3.360 6.588 9.281 12.933 3.932 0.569 
ITIH4 88.610 49.775 0.000 75.873 0.000 82.429 0.866 
CP (ceruloplasmin) 9.466 3.255 9.572 8.429 8.456 5.714 0.966 
ALB 127.748 78.491 164.563 87.319 80.559 69.741 0.156 
C5 8.839 2.630 15.469 10.897 12.148 14.774 0.403 
SERPINA3K 273.259 205.081 121.236 289.055 429.646 403.291 0.047 
SERPINA3M 16.396 16.914 9.326 8.759 19.529 14.845 0.969 
MUG1 10.834 7.784 12.325 9.922 15.901 11.912 0.363 
FGB 4.749 3.675 5.403 15.224 6.364 8.601 0.114 
ITIH1 12.593 3.898 1.433 4.037 2.250 3.421 0.469 
ITIH2 7.245 3.737 15.109 6.773 2.157 5.466 0.344 
TF 31.137 30.430 54.064 30.205 32.208 23.741 0.296 
C3 0.000 29.759 53.133 73.756 57.678 97.015 0.064 
GPLD1 0.000 9.446 13.889 10.871 4.848 15.968 0.621 
VTN 2.390 3.698 0.000 0.000 0.000 2.164 0.372 
LIFR 12.552 7.284 0.000 10.059 10.279 0.000 0.975 
DOCK8 0.544 0.421 1.238 0.436 0.972 0.493 0.759 
AMBP 6.546 5.065 3.723 7.868 0.000 0.000 0.416 
FGG 13.099 4.054 5.961 8.398 9.362 0.000 0.682 
HRG 4.262 0.000 2.424 0.000 3.808 0.000 0.617 
        
The spectral counts for each protein that was identified in at least 3 of the 6 excised gel bands submitted for 
mass-spectrometry are listed.  Spectral counts were normalized with the Abacus computational tool.  A 
student’s t-test was used for statistical analysis, with p < 0.05 considered statistically significant.  Only one 
protein, SERPINA3K, was statistically significantly lower in abundance in the Lman1-/- plasma samples 
than in the Lman1+/+ control samples in this analysis.  Complement component C3 was also under-
represented in Lman1-/- plasma samples (borderline significant). 
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Table 4-3:  QSPEC analysis reveals two proteins that are significantly under-
represented in Lman1-/- plasma as compared to Lman1+/+ plasma 
Protein Z-statistic False Discovery Rate Function 
Serine protease inhibitor A3K 
(SERPINA3K) -4.703 0.000004 
Protease 
inhibitor 
Complement component 3 -4.198 0.000097 Serine   protease 
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Figure 4-1:  LMAN1 and MCFD2 protein fragments for yeast two-hybrid assay 
 (A) LMAN1 is a type 1 transmembrane protein.  SS, signal peptide sequence; CRD, 
carbohydrate recognition domain; COIL, coiled coil domain; TMD, transmembrane 
domain; CD, cytoplasmic domain; KKFF, di-phenylalanine ER exit motif, di-lysine 
retrieval signal.  The luminal domain and the cytoplasmic domain were tested as separate 
Y2H “baits” to eliminate technical difficulties associated with testing transmembrane 
proteins.  (B) MCFD2 is a soluble protein with a signal peptide sequence (SS) and two 
EF-hand domains.  It binds to LMAN1 via a Ca2+-dependent interaction.  The protein 
fragments tested by Y2H are indicated by brackets. 
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Figure 4-2:  LMAN1 interacts with all four mammalian SEC24 paralogs 
COS cells were co-transfected with FLAG-tagged LMAN1 and one of four RFP-tagged 
SEC24 paralogs (A-D).  As indicated in lanes 1-4 of the Western blot, the co-
transfections were successful, with high expression of both FLAG-LMAN1 and each 
RFP-SEC24.  A negative control transfection (lane 5 under “Input,” indicated by “-”) was 
transfected only with FLAG-LMAN1.  An anti-FLAG co-immunoprecipitation 
experiment was performed (“FLAG-IP” lanes) to isolate LMAN1 and its binding partners 
in complex.  FLAG-LMAN1 was highly enriched and successfully precipitated from the 
total cell lysate.  RFP-SEC24A (lane 6), RFP-SEC24B (lane 7), RFP-SEC24C (lane 8), 
and RFP-SEC24D (lane 9) co-immunoprecipitated with LMAN1, indicating that all four 
SEC24 paralogs physically interact with LMAN1.   
FLAG%
RFP%
Input% FLAG-IP%
FLAG-Lman1%+%%
RFP-Sec24:%%%%%%%%%%%%%%%%A%%%%%B%%%%%C%%%%%D%%%%%%-%%%%%A%%%%%%B%%%%%%C%%%%%D%%
FLAG%Lman1&and&RFP%Sec24&co%immunoprecipita5on&in&COS&cells&
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Figure 4-3:  SEC23A and SEC23B both interact with all four SEC24 paralogs 
COS cells were co-transfected with (A) FLAG-tagged SEC23A and each of four RFP-
tagged SEC24 paralogs (A-D) individually, or with (B) FLAG-tagged SEC23B and each 
of the four RFP-SEC24 paralogs (A-D) individually.  As indicated in lanes 1-4 of each 
Western blot (“Input”), FLAG-SEC23 and each RFP-SEC24 were successfully co-
expressed.  An anti-FLAG co-immunoprecipitation experiment was performed (“FLAG-
IP” lanes) to isolate SEC23 and its interacting proteins.  As demonstrated by Western blot 
analysis of the co-immunoprecipitation product (“FLAG-IP”), the FLAG-SEC23 proteins 
were highly enriched and successfully precipitated from the total cell lysate.  Similarly, 
RFP-SEC24A (lane 5), RFP-SEC24B (lane 6), RFP-SEC24C (lane 7), and RFP-SEC24D 
(lane 8) each co-immunoprecipitated with SEC23A and SEC23B, indicating that each of 
the SEC24 paralogs physically interacts with both SEC23 paralogs.   
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Figure 4-4:  Differential abundance of a plasma protein in Lman1+/+ and Lman1-/- 
mice  
Platelet-poor plasma from wild-type mice and Lman1-/- mice was analyzed by SDS-
PAGE to potentially identify plasma proteins with differential abundance.  As indicated 
by the black arrow, a band of ~ 100 kDa was of lower abundance in the plasma samples 
from Lman1-/- mice as compared to Lman1+/+ mice.  Each lane represents a different 
animal.  The band of interest was excised from three Lman1+/+ lanes and three Lman1-/- 
lanes.  These 6 gel fragments were submitted for mass-spectrometry in order to identify 
the protein, and to determine if its abundance is different between Lman1+/+ mice and 
Lman1-/- mice.  
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Figure 4-5:  Plasma ceruloplasmin is not reduced in Lman1-/- mice 
Platelet-poor plasma from wild-type mice and Lman1-/- mice was analyzed by Western 
blot to determine whether ceruloplasmin plasma levels are reduced in Lman1-/- mice.  The 
primary ceruloplasmin band (indicated by the arrow) represents full-length native 
ceruloplasmin, while the slightly lower molecular weight band represents a degradation 
product.  Although there is a slight trend for Lman1-/- mice to have more of the 
degradation product as compared to wild-type mice, overall the abundance of 
ceruloplasmin in Lman1+/+ and Lman1-/- plasma samples is indistinguishable.  Each lane 
represents a different animal.   
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Figure 4-6:  Isolation of liver lysosomes  
(A) Schematic of the cell fractionation procedure to isolate lysosomes from mouse liver 
tissues.  Liver tissue samples were pulverized and homogenized, and the lysate was 
centrifuged to obtain a post-nuclear supernatant.  This supernatant was applied to an 18% 
Percoll solution for further centrifugation, and the resulting heavy membrane fraction was 
further centrifuged and fractionated on an iodixanol Gradient.  (B) The fractions 
containing heavy membrane structures from (A) were applied to an iodixanol gradient (8-
27%) in order to separate lysosomes and mitochondria.  Western blot analysis of the 
resulting fractions was used to identify which fractions demonstrated high lysosome 
enrichment, but little to no mitochondrial contamination.  A LAMP-1 antibody was used 
as a lysosome marker, and a Complex II antibody was used as a mitochondrial marker.  
The first 7 to 8 fractions from the iodixanol gradient (~8-15%) were reproducibly found 
to be highly enriched for lysosomes and largely depleted of mitochondria.  The first 7 
fractions of each prep were therefore pooled and submitted for mass-spectrometry 
analysis. 
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Figure 4-7:  Lysosome preps are highly enriched and appear nearly pure 
Lysosomes were isolated from fresh mouse liver tissue by differential density 
centrifugation on sucrose and iodixanol gradients.  Serial dilutions of the resulting 
lysosome fraction (from 20% down to 0.625%) were analyzed by Western blot for a 
number of cell markers to confirm lysosome enrichment and sample purity.  The positive 
control represents total liver lysate (input). 
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Figure 4-8:  Gel fractionation of pooled lysosome preps for mass-spectrometry 
The final product of the lysosome prep from mouse liver tissues (i.e. the pooled product 
of iodixanol fractions #1-7 in Figure 4-6B) was submitted to SDS-PAGE in order to 
assess for sample complexity.  Although some subtle differences between the four 
lysosomal preps are detectable visually, there are no obvious differences in protein 
content or abundance between the wild-type and Lman1-/- samples.  However, the 
complexity of these samples was quite high (i.e. there are many proteins in each prep), so 
each gel lane was cut into 5 different gel slices and submitted to mass-spectrometry 
individually. 
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CHAPTER 5 : 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
CHARACTERIZATION OF AN ALLELIC SERIES OF MURINE LMAN1 
MUTATIONS  
 
An LMAN1-deficient mouse model (Lman1gt1/gt1) with <1% of normal Lman1 gene 
expression was previously shown to reproduce the human F5F8D phenotype, but with 
important phenotypic differences as compared to human F5F8D patients: less severe FV 
and FVIII reduction and partial lethality.95  To address these differences and to further 
characterize the role of the LMAN1 cargo receptor, we generated an independent, 
hypomorphic conditional gene-trap allele (Lman1cgt) and a true null allele with no Lman1 
expression (Lman1-).  We demonstrated a correlation between Lman1 gene expression 
and the levels of LMAN1-dependent cargo secretion for FV, FVIII, and A1AT.  
Lman1cgt/cgt mice retain ~7% of normal Lman1 expression and have plasma FV and FVIII 
activity levels that are ~70% of wild-type levels.  In contrast, null Lman1-/- mice exhibit 
plasma FV and FVIII levels that are ~50% of wild-type levels, a reduction of FV and 
FVIII plasma activity that is less severe than that observed in human F5F8D patients, 
with ~10-15% of normal levels.  This finding demonstrates a threshold effect for 
LMAN1-mediated secretion, such that total loss of LMAN1 function in the mouse only 
results in ~50% reduction of FV and FVIII secretion.  These data indicate that an 
unknown parallel or compensatory mechanism exists in mice for the secretion of the 
other ~50% of the plasma FV and FVIII.  The correlation between Lman1 expression and 
LMAN1-dependent cargo secretion also suggests that genetic variation at the LMAN1 
locus may account for variation in FV and FVIII levels in human populations, as well as 
for some patients with mild deficiencies in FV and FVIII not previously identified as 
F5F8D. 
 111 
   
We also demonstrated that Lman1-/- mice exhibit a strain-specific, partially penetrant, 
perinatal lethality, confirming the previous report of lethality in Lman1gt1/gt1 mice.  
Finally, Lman1-/- mice exhibit a moderate, isolated thrombocytopenia that is not observed 
in hypomorphic Lman1cgt/cgt mice, heterozygous Lman1+/- mice, or Mcfd2-/- mice, 
suggesting a role for a novel platelet-specific LMAN1 cargo, or an unknown function of 
LMAN1 in platelet development.  Additional studies to characterize Lman1-/- mice for a 
defect in platelet secretory granules or the development of megakaryocytes and platelets 
are currently underway.  
 
 
ENDOTHELIAL CELLS ARE THE PRIMARY SOURCE OF FVIII 
BIOSYNTHESIS IN VIVO 
 
The primary cellular source of FVIII biosynthesis has been controversial, with 
contradictory evidence supporting an endothelial or hepatocyte origin.  Lman1 
conditional knockout mice were studied to determine the relative contribution of 
hepatocytes and endothelial cells to the plasma FVIII pool.  Mice deficient for LMAN1 
in hepatocytes exhibit low plasma FV activity levels, but normal FVIII plasma activity 
levels.  In contrast, mice deficient for LMAN1 in the endothelium exhibit normal plasma 
FV levels, but low FVIII levels, with FVIII reduction comparable to that observed in the 
ubiquitous Lman1 knockout mice.  These data indicate that endothelial cells are the 
primary biosynthetic source of murine FVIII, and that hepatocytes make no significant 
contribution to the plasma FVIII pool.  Utilizing RiboTag mice and polyribosome 
immunoprecipitation, we performed endothelial cell-specific mRNA isolation and qPCR 
analyses to confirm that endothelial cells highly express F8, and to explore the 
heterogeneity of F8 expression in different vascular beds.  Endothelial cells from 
multiple, but not all, tissues contribute to the plasma FVIII pool in the mouse.  
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PROTEOMIC APPROACHES TO IDENTIFY LMAN1 FUNCTIONS AND 
INTERACTING PROTEINS 
 
The identification of new LMAN1 cargos and interacting proteins that regulate LMAN1 
function is important to further define LMAN1’s role as an ER cargo-receptor.  We 
demonstrated by co-immunoprecipitation that LMAN1 interacts with all four SEC24 
paralogs (A-D), which are critical components of the inner COPII coat.  We also 
demonstrated that both SEC23 paralogs (SEC23A and SEC23B) interact with all four 
SEC24 paralogs, implying that 8 possible SEC23-SEC24 heterodimer combinations are 
available as building blocks for COPII vesicles.  The biologic significance and potential 
functional differences between these heterodimers are unknown.  Different heterodimers 
could serve tissue- or cargo-specific functions to facilitate the selective recruitment of 
secretory cargos into budding COPII vesicles.  We also performed a high-throughput 
yeast two-hybrid study to identify potentially novel protein-protein interactions for the 
LMAN1 luminal domain, the LMAN1 cytoplasmic domain, and the MCFD2 protein.  
Unfortunately this screen did not identify reproducible interactions (including 
interactions with known LMAN1 cargo proteins), perhaps due to the technical limitations 
of performing a Y2H assay for a membrane protein that is primarily located in the ER 
lumen (where protein-protein interactions form under very different conditions than 
would occur in the yeast nucleus). 
 
Taking advantage of our mouse model of F5F8D, we attempted several cell fractionation 
procedures from liver lysates of F5F8D mice and wild-type controls in order to isolate 
ER, Golgi, and lysosome secretory compartments for mass-spectrometry analysis.  
Although we successfully enriched for lysosomes and appeared to eliminate nearly all 
other cellular contaminants from our preps, as demonstrated by Western blot analyses, 
the mass-spectrometry analyses of these samples revealed the presence of many non-
lysosomal membrane and secretory proteins that prevented the useful comparison of 
lysosomal contents across different samples.  Further optimization to achieve cleaner, 
simpler cell fractions for mass-spectrometry is necessary to resolve this issue, perhaps 
prepared from cultured cells rather than from tissues.  Finally, we observed an ~100 kDa 
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protein of interest upon SDS-PAGE analysis of plasma samples from wild-type and 
Lman1-/- mice.  The apparent protein was present in lower abundance in the plasma of 
Lman1-/- mice as compared to that of wild-type mice.  Mass-spectrometry analysis of this 
~100 kDa gel band from both wild-type and Lman1-/- mice demonstrated that two 
proteins were significantly under-represented in the plasma of Lman1-/- mice.  The first 
protein was SERPINA3K (also known as “serine (or cysteine) peptidase inhibitor, clade 
A, member 3K,” or as alpha-1 antichymotrypsin).  Interestingly, SERPINA3K is a 
member of the same clade of SERPINS (serine proteinase inhibitors) as the highly 
homologous protein alpha-1 antitrypsin (A1AT, also known as SERPINA1), another 
previously-reported LMAN1 dependent cargo (see Chapter 4).  The second under-
represented protein in the Lman1-/- plasma samples was Complement Component C3, a 
serine protease.  We are currently working to confirm these preliminary results and to 
further explore SERPINA3K and/or Complement Component C3 as putative LMAN1 
cargos. 
 
 
FUTURE DIRECTIONS 
 
 
Our incomplete understanding of LMAN1’s role in the secretory pathway is an important 
scientific problem.  In the future, our efforts will focus on addressing several fundamental 
questions in LMAN1 biology and F5F8D pathophysiology.  As described in the 
following sections, the molecular basis for the apparent differences in F5F8D 
presentation in mice and humans may be explained by identifying a compensatory or 
parallel mechanism for LMAN1 cargo secretion.  It is also possible that the impaired 
secretion of a novel LMAN1 cargo that is unique to mice results in perinatal lethality, 
which would account for the lack of known perinatal death or elevated miscarriage rates 
associated with F5F8D in humans.  In addition, further study will reveal the molecular 
etiology of the thrombocytopenia observed in Lman1-/- mice, which has not been 
observed in human patients.  However, a relatively subtle thrombocytopenia may have 
been missed in humans for several reasons, including the small number of patients, the 
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wide range of platelet count values that are considered clinically normal, and the inter-
laboratory variability in CBC analyses and blood analyzers.   However, identification of a 
platelet defect in human F5F8D patients would be an important finding both for the 
further characterization of LMAN1-dependent protein secretion, and for understanding 
platelet biology. 
 
Identify alternate mechanism(s) for LMAN1 cargo secretion 
Complete LMAN1 or MCFD2 deficiency in both mice and humans does not cause FV 
and FVIII plasma levels to be reduced to zero, but only to ~50%, so an alternate secretion 
mechanism for these cargos clearly exists.  Though a novel ER cargo receptor, similar in 
function to LMAN1, could be responsible for this alternate secretion pathway, no other 
mammalian ER cargo receptors are currently known, despite significant efforts to identify 
them.  Physical cargo/receptor interactions are transient protein-protein interactions, 
unlike a stable complex that may be isolated intact, and may be difficult to detect.  We do 
not currently know whether an alternate FV and FVIII secretion mechanism is utilized 
constitutively, or only in the absence of LMAN1 as an upregulated compensatory 
mechanism.  Similarly, do other LMAN1 cargos also utilize the same alternate 
mechanism?  Given that some controversy still remains regarding the two models of ER-
to-Golgi transport (bulk-flow vs. receptor-mediated),192 we must also consider the 
possibility that in the absence of LMAN1, at least some FV and FVIII is secreted via 
bulk-flow rather than by receptor-mediated ER-to-Golgi transport.  However, the finding 
that 50% of FV and FVIII are secreted to the plasma in Lman1-/-  mice makes bulk-flow a 
less likely explanation, because bulk-flow alone is unlikely to be able to support such a 
high rate of secretion.71 
 
Lman1-/- and Mcfd2-/- mice both exhibit FV and FVIII levels that are ~50% of normal.  
Since LMAN1 and MCFD2 work together in the same receptor complex (i.e. same 
“pathway”), double knockout mice are expected to also exhibit ~50% of normal FV and 
FVIII levels.  If the double knockout mice exhibit a more severe reduction in FV and 
FVIII plasma levels as compared to the single knockout mice, this will indicate that 
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LMAN1 and MCFD2 are not epistatic, and suggest an alternative interaction for one or 
both of these proteins.  
 
As an initial approach to identify potential alternate secretion mechanisms for LMAN1 
cargos, and to understand the cellular response to LMAN1 deficiency, RNAseq could be 
used to determine the gene expression changes that occur in the absence of LMAN1.  If 
an alternate receptor complex or secretory pathway is upregulated in LMAN1-deficient 
cells, it is possible that differences in the RNAseq profiles of wild-type cells and Lman1-/- 
cells will reveal these compensatory cellular changes. If no differences are observed at 
the RNA level, this does not rule out a compensatory upregulation at the protein level 
(due to increased translation and/or decreased protein degradation).  RNAseq and/or 
qPCR analysis will also reveal potential upregulation of unfolded protein response (UPR) 
genes and markers of ER stress resulting from impaired secretion of cargos, which might 
serve as a cellular trigger for an alternate secretion mechanism for LMAN1 cargos.  It is 
possible that LMAN1 cargos are upregulated themselves in the absence of LMAN1, as a 
way to compensate for loss of their usual secretory receptor complex.  This finding might 
suggest a feedback loop or sensing mechanism so that LMAN1 cargos are upregulated 
when their secretion is impaired.  In this case, RNAseq would reveal upregulation of F5, 
F8, and A1AT in Lman1-/- cells as compared to wild-type cells. 
 
Whole-genome functional screens represent another appealing approach to identify the 
alternate secretion mechanism for FV and FVIII.  Whole-genome CRISPR (clustered 
regularly interspaced short palindromic repeats)-Cas9 knockout screens have recently 
been developed to efficiently and systematically knockout almost every gene in the 
genome for use in high-throughput studies.193,194  This approach was used to target 
18,080 genes in human cells to identify genes that are essential for cell viability in cancer 
and pluripotency, as well as to identify genes involved in resistance to vemurafenib.193  
This approach could be applied to LMAN1-deficient cells (hepatocytes for FV, 
endothelial cells for FVIII) to identify novel components of the alternate secretion 
pathway for FV and FVIII.  In this system, LMAN1-deficient cells would still secrete 
~50% of normal levels of FV or FVIII.  However, in the presence of a CRISPR-induced 
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genetic mutation that inhibits the alternate FV/FVIII secretion pathway, the secretion of 
these coagulation factors would drop from ~50% down to as low as 0% secretion.  This 
approach for a secreted protein such as FV or FVIII would require some technical 
adaptation in order to determine whether the protein of interest was secreted or not in a 
high-throughput manner.  One possible approach would be to engineer a 
glycosylphosphatidylinositol (GPI) anchor onto the secreted cargo, which would cause it 
to be bound to the cell membrane.  Flow-cytometry cell sorting could then be used to sort 
the cells based on the presence or absence of the GPI-anchored cargo on the cell surface.  
Cells without the GPI-anchored protein on their surface would represent cells in which a 
CRISPR-induced mutation had impaired the alternate secretion mechanism for the 
LMAN1 cargo.  Next-generation sequencing of the clones that did not display the GPI–
anchored cargo on the cell surface could reveal genes responsible for the alternate FV and 
FVIII secretion pathway.  
 
Elucidate the etiology of Lman1-/- thrombocytopenia 
The finding that Lman1-/- mice are moderately thrombocytopenic is a surprising result, 
suggesting that LMAN1 may serve as a cargo receptor for a platelet- or megakaryocyte-
specific secreted protein that is critical for platelet development or survival in the plasma.  
Alternatively, LMAN1 could serve as an ER cargo receptor for a growth factor that is 
secreted from another (non-megakaryocyte) cell type.  A number of studies could help 
elucidate the etiology of this platelet defect.   
 
First, it is critical to determine if the defect is cell intrinsic (i.e. due to a defect in the 
megakaryocyte/platelet lineage) as opposed to a defect in another cell type (bone marrow 
hematopoietic cells, bone marrow stromal cells, or other cell types) that have a 
secondary, downstream effect of thrombocytopenia.  We could utilize conditional Lman1 
knockout mice (Chapter 2) in which Lman1 is specifically deleted in the 
megakaryocyte/platelet lineage (Pf4-Cre) or the hematopoietic compartment (Vav1-Cre).  
If the thrombocytopenia phenotype results from an intrinsic defect in megakaryocytes or 
platelets, then the phenotype should be reproduced in the Lman1 platelet (Pf4) and 
hematopoietic (Vav1) knockout mice.  Alternatively, if thrombocytopenia is observed in 
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the hematopoietic compartment knockout mice, but not the megakaryocyte/platelet-
specific knockout mice, this finding would indicate that the defect arises in the bone 
marrow, but is not intrinsic to the megakaryocyte/platelet lineage.  If hematopoietic 
(Vav1) and megakaryocyte/platelet (Pf4) conditional knockout mice have normal platelet 
counts, this would suggest that the thrombocytopenia observed in Lman1-/- mice is an 
indirect effect of a defect in another cell type.  An intriguing possible explanation would 
be a defect in the secretion of thrombopoietin (also known as megakaryocyte growth and 
development factor) from the liver as the cause of Lman1-/- thrombocytopenia.  
Thrombopoietin is a glycoprotein synthesized in the liver that simulates the production 
and differentiation of megakaryocytes, the cells that generate platelets.  To explore this 
possibility, we would measure platelet counts in conditional knockout mice with Lman1 
specifically deleted in the hepatocytes.  A low platelet count in hepatocyte-specific 
Lman1 knockout mice would suggest that an LMAN1 cargo secreted from the liver is 
responsible for the thrombocytopenia of Lman1-/- mice.  These tissue-specific knockout 
studies are currently underway. 
 
If the thrombocytopenia defect is intrinsic to the megakaryocyte/platelet lineage, it would 
be important to determine if the thrombocytopenia is associated with a secretory defect in 
megakaryocytes/platelets.  Platelets are highly secretory cells that release the contents of 
alpha-granules and dense-granules into the plasma upon activation.  The contents of 
alpha-granules and dense-granules are all secretory cargos that must be properly 
synthesized and transported from the ER to the Golgi and the secretory granules.  A 
defect in the ER-to-Golgi transport of these platelet secretory cargos would be expected 
to be identified by comparing the contents of platelet alpha granules195 and dense 
granules196 from wild-type control mice and Lman1-/- mice by mass-spectrometry.  
 
Megakaryocyte differentiation studies197 in cell culture for wild-type and Lman1-/- cells 
could be performed to assess a potential defect in cell lineage, such as in pro-platelet 
formation.  Similarly, FACS analysis of bone marrow cells from wild-type and Lman1-/- 
mice may reveal a potential block in platelet differentiation in Lman1-/- mice, although 
this approach may not reveal a defect since the thrombocytopenia phenotype in Lman1-/- 
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mice is mild.  A block in platelet differentiation would indicate that LMAN1 plays a role 
in platelet formation.  These experiments may help distinguish between impaired platelet 
differentiation and premature platelet destruction.   
 
Any putative LMAN1-dependent cargos in platelets or megakaryocytes could be 
validated in our murine F5F8D mice, as well as in human patients and control subjects.  
The finding of a platelet defect in F5F8D patients would be an important clinical and 
translational result.  In order to validate the putative cargo, immunofluorescence studies 
could be used to demonstrate accumulation in the ER in the absence of LMAN1.  In vitro 
budding assays could be performed to determine whether incorporation of the putative 
cargo into COPII vesicles is dependent upon LMAN1.   
 
Identification of novel LMAN1 cargos and interacting proteins 
Since purification of transmembrane proteins with their associated binding partners is 
technically difficult and not well suited to affinity-purification mass-spectrometry, 
another sensitive method of capturing and identifying LMAN1’s protein-protein 
interactions is desirable.  Biotinylation of LMAN1 proximal and interacting proteins 
(cargos, adaptors, regulators) in vivo can be achieved by utilizing a promiscuous biotin 
ligase fusion protein (LMAN1-BirA*), a technique based on the fusion of a modified 
biotin ligase (BirA*) to a protein of interest.198  The BirA* attaches a biotin to the 
LMAN1-fusion protein and its interacting proteins (proximity-dependent biotinylation).  
The strong interaction between biotin and streptavidin can then be utilized to affinity-
purify labeled proteins, followed by mass-spectrometry for identification.  In vivo 
biotinylation is particularly appropriate for the identification of novel LMAN1 cargos and 
interacting proteins because it is suitable for detecting interacting and neighboring 
proteins in the native cellular environment, and the biotinylation is efficient enough to 
label proteins that only transiently interact with LMAN1 (such as cargos or adaptors).  In 
fact, in vivo biotinylation has already been successfully applied for the biotinylation of 
proteins within the secretory pathway.199  The in vivo biotinylation technique could be 
applied not only to LMAN1 (to identify new cargos, LMAN1-adaptors, and regulators of 
its function), but also to MCFD2 in order to potentially identify other ER cargo receptors 
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that it might pair with, and/or other secretory cargos that are MCFD2-dependent for 
secretion.  Similarly, FV-BirA* and FVIII-BirA* fusion proteins might be used to 
biotinylate other cargo receptors or components that are responsible for the alternate, 
LMAN1-independent secretion of FV and FVIII.  One potential limitation of the in vivo 
biotinylation approach is that the BirA* fusion may cause the targeted protein to mis-
fold, and/or may impair its endogenous protein-protein interactions.  The effect of the 
BirA* fusion on the function, cellular localization, and binding pattern of LMAN1 and 
any other targeted proteins would therefore have to be evaluated on a case-by-case basis 
to ensure the validity of this experimental approach.  
 
Finally, since LMAN1 has a luminal carbohydrate recognition domain and is a mannose-
specific lectin, glycopeptide enrichment of plasma or cell samples represents another 
useful mass-spectrometry based approach to enrich a biological sample for presumed 
LMAN1 cargos.  Glycoproteins are often low in abundance in a biologic sample or 
complex mixture, and glycopeptide enrichment compensates for the otherwise low 
number of spectral counts assigned to glycoproteins in mass-spectrometry studies.  
Glycopeptide enrichment, in combination with quantitative proteomic methods such as 
SILAC (discussed in Chapter 4), are expected to generate high-quality, targeted 
proteomic profiling data for the characterization of individual secretory compartments in 
mammalian cells. 
 
Although further work and technical optimization of proteomic-based assays is required 
to identify novel LMAN1 secretory cargos, these approaches are expected to reveal 
LMAN1’s full complement of cargos and to further elucidate the fundamental cellular 
process of receptor-mediated cargo secretion.  
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